[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"pancreatic-cancer\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:pancreatic-cancer":28},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,393,0,25,[9,60,86,111,135,158,187,218,244,265,305,332,361,394,419,443,465,486,511,542,568,596,622,653,695],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":16,"eligibilityCriteria":17,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":36,"overallStatus":47,"whyStopped":4,"lastUpdateSubmitDate":48,"lastUpdatePostDateStruct":49,"startDateStruct":52,"completionDateStruct":54,"leadSponsor":56,"locationsCount":59},"100636166","phase-3-atebimetinib--gnp-as-a-first-line-treatment-in-patients-with-metastatic-pancreatic-adenocarcinoma-100636166",false,"NCT07562152","Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma","A Phase 3 Randomized, Open-Label Study of Atebimetinib in Combination With the Modified Gemcitabine and Nab-Paclitaxel Regimen Versus the Standard Gemcitabine and Nab-Paclitaxel Regimen for the Treatment of Patients With Metastatic Pancreatic Ductal Pancreatic Adenocarcinoma Cancer (MAPKeeper 301)","MAPKeeper 301","Inclusion Criteria:\n\n* Must be ≥18 years of age\n* Must have confirmed diagnosis according to AJCC staging as follows:\n\n  * Metastatic pancreatic adenocarcinoma within 12 weeks prior to screening\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1\n* Participants must be treatment naive as follows:\n\n  * First-line PDAC participants will have received no previous systemic anti-cancer therapy\n* Must have evidence of measurable disease (at least one target lesion) per RECIST v1.1 criteria\n* Adequate organ function, hepatic function, coagulation studies and protocol determined clinical laboratory values\n\nExclusion Criteria:\n\n* Inability to swallow oral medications\n* Participant has squamous, adenosquamous, neuroendocrine (carcinoid, islet cell) or acinar pancreatic carcinoma\n* Participants with only locally advanced disease\n* Symptomatic, untreated, or actively progressing known central nervous system (CNS) metastases","ALL","18 Years",{"count":21,"type":22},510,"ESTIMATED","INTERVENTIONAL",[25],"PHASE3","The purpose of this study is to evaluate the safety and efficacy of atebimetinib in combination with modified GnP compared with SOC GnP alone.",[28,29,30,31,32,33,34,35],"Pancreatic Cancer","Pancreatic Cancer Metastatic","PDAC","PDAC - Pancreatic Ductal Adenocarcinoma","Pancreatic Ductal Adenocarcinoma","Pancreatic Adenocarcinoma Metastatic","Pancreatic Ductal Adenocarcinoma (PDAC)","Pancreatic Adenocarcinoma",[37,38,39,40,41,42,43,44,45,46],"mitogen-activated protein kinase (MAPK)","MAPK","MEK","metastatic cancer","gemcitabine","nab-paclitaxel","nab-p","atebimetinib","KRAS","pan-RAS","RECRUITING","2026-08-20",{"date":50,"type":51},"2026-08-21","ACTUAL",{"date":53,"type":51},"2026-06-05",{"date":55,"type":22},"2029-02",{"name":57,"class":58},"Immuneering Corporation","INDUSTRY",38,{"id":61,"slug":62,"hasResults":12,"nctId":63,"briefTitle":64,"officialTitle":65,"acronym":66,"eligibilityCriteria":67,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":68,"targetDuration":4,"studyType":23,"phases":70,"briefSummary":71,"conditions":72,"keywords":74,"overallStatus":47,"whyStopped":4,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":78,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":83,"locationsCount":85},"100641682","phase-3-study-of-zoldonrasib--chemo-of-investigators-choice-vs-placebo--chemo-of-investigators-choice-as-first-line-treatment-in-metastatic-kras-g12d-mutated-pancreatic-adenocarcinoma--rasolute-305--100641682","NCT07621718","Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of Investigator's Choice as First-line Treatment in Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma ( RASolute 305 )","RASolute 305: A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Investigator Choice of Chemotherapy (Modified FOLFIRINOX or Gemcitabine Plus Nab-Paclitaxel) With or Without Zoldonrasib (RMC-9805) as First-line Treatment in Patients With Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma","RASolute 305","Inclusion Criteria:\n\n* At least 18 years old and has provided informed consent.\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.\n* Histologically or cytologically confirmed pancreatic adenocarcinoma.\n* Diagnosis of metastatic disease ≤ 6 weeks prior to screening.\n* Documented KRAS G12D mutation status.\n* Measurable disease per RECIST v1.1.\n* Adequate organ function (bone marrow, liver, kidney, coagulation).\n* Able to take oral medications.\n\nExclusion Criteria:\n\n* Prior treatment with systemic anticancer therapy in unresectable locally advanced or metastatic setting.\n* Prior systemic RAS-targeted therapy any time prior to randomization.\n* Presence of other known driver mutations with approved targeted therapies\n* Active or known history of untreated central nervous system metastatic disease.\n* Any conditions that may affect the ability to take or absorb study drug.\n* Major surgery within 28 days prior to randomization.\n* Patient is unable or unwilling to comply with protocol-required study visits or procedures.",{"count":69,"type":22},670,[25],"The purpose of this study is to evaluate the efficacy of an investigational RAS(ON) inhibitor administered in combination with chemotherapy compared to placebo in combination with chemotherapy.",[28,29,30,31,34,33,35,73],"Pancreatic Adenosquamous Carcinoma",[28,30,32,75,45,76,29,33,73,35],"RAS","RAS Mutation","2026-08-19",{"date":50,"type":51},{"date":80,"type":51},"2026-05-22",{"date":82,"type":22},"2030-04-22",{"name":84,"class":58},"Revolution Medicines, Inc.",6,{"id":87,"slug":88,"hasResults":12,"nctId":89,"briefTitle":90,"officialTitle":91,"acronym":4,"eligibilityCriteria":92,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":93,"targetDuration":4,"studyType":23,"phases":95,"briefSummary":97,"conditions":98,"keywords":99,"overallStatus":47,"whyStopped":4,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":102,"startDateStruct":103,"completionDateStruct":105,"leadSponsor":107,"locationsCount":110},"100526921","phase-1-radiotherapy-in-combination-with-tti-101-in-borderline-resectable-and-locally-advanced-pancreatic-ductal-adenocarcinoma-100526921","NCT06141031","Radiotherapy in Combination With TTI-101 in Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma","Phase I\u002FIB Trial of Radiotherapy in Combination With TTI-101 in Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma","Inclusion Criteria:\n\n* Pathologically confirmed pancreatic adenocarcinoma that is borderline resectable or locally advanced as defined by NCCN guidelines, with no expected arterial resection\u002Freconstruction.\n* Patients who are borderline resectable must have completed standard of care induction chemotherapy between 1 and 3 weeks prior to planned start of TTI-101 + SBRT. Patients who exceed this window may be considered for enrollment if they complete an additional cycle of induction chemotherapy prior to initiation of study treatment (per provider discretion). The amount of induction chemotherapy cycles allowed will be left to the discretion of the treating medical oncologist. There is no timing restriction for patients with locally advanced disease.\n* At least 18 years of age.\n* ECOG performance status ≤ 2\n* Adequate bone marrow and organ function as defined below:\n\n  * Absolute neutrophil count ≥ 1.0 K\u002Fcumm\n  * Platelets ≥ 70 K\u002Fcumm\n  * Hemoglobin ≥ 9.0 g\u002FdL (patients may be transfused to meet this criterion)\n  * Total bilirubin ≤ 2 mg\u002FdL\n  * AST(SGOT)\u002FALT(SGPT) ≤ 3.0 x IULN\n  * Serum albumin ≥ 2.8 g\u002FdL\n  * Ionized calcium ≤ 1.5 mmol\u002FL, calcium ≤ 12 mg\u002FdL, or corrected serum calcium ≤ IULN)\n  * Measured creatinine clearance \\> 40 mL\u002Fmin or calculated creatinine clearance \\> 40 mL\u002Fmin by Cockcroft-Gault or by 24-hour urine collection for determination of creatinine clearance (calculations in protocol).\n* Able to swallow pills.\n* INR and aPTT ≤ 1.5 x IULN unless patient is receiving anticoagulant therapy (in which case INR and PTT must be within therapeutic range of intended use of anticoagulants)\n* The effects of TTI-101 on the developing human fetus are unknown. For this reason, women of childbearing potential and men must agree to use at least 1 highly effective method of contraception from screening through the duration of study participation, and for 30 days after last dose of TTI-101. Should a woman become pregnant or suspect she is pregnant while participating in this study or should a man suspect he has fathered a child, s\u002Fhe must inform the treating physician immediately.\n* Agreement to adhere to Lifestyle Considerations throughout study duration.\n* Ability to understand and willingness to sign an IRB approved written informed consent document. Legally authorized representatives may sign and give informed consent on behalf of study participants.\n\nExclusion Criteria:\n\n* Prior treatment for pancreatic cancer in the past 2 years (outside of the induction chemotherapy received for the current diagnosis).\n* Prior or concurrent malignancy whose natural history has the potential to interfere with the safety or efficacy assessment of the investigational regimen. Patients with prior or concurrent malignancy that does NOT meet that definition are eligible for this trial.\n* Currently receiving any other investigational agents or has participated in a study of an investigational agent or using an investigational device overlapping with study treatments within 3 months preceding study entry at the discretion of the PI.\n* A history of allergic reactions attributed to compounds of similar chemical or biologic composition to TTI-101 or other agents used in the study.\n* Uncontrolled intercurrent illness including but not limited to: ongoing or active infection (fungal, bacterial, or viral (including COVID-19)), sepsis, acute and chronic active infectious disorders (including viral and nonmalignant medical illnesses that are uncontrolled or whose control may be jeopardized by the complications of this study therapy), and chronic pancreatitis. Patients with a recent COVID-19 diagnosis must have fully recovered from all COVID-19 symptoms for 2 weeks prior to the start of study treatment.\n* Significantly impaired cardiac function such as symptomatic congestive heart failure with NYHA Class III or IV, unstable angina pectoris, myocardial infarction within the last 12 months prior to study entry, serious cardiac arrhythmia (including QTc prolongation of \\> 470 ms and\u002For pacemaker), or prior diagnosis of congenital long QT syndrome.\n* Ongoing toxicity due to induction chemotherapy, unless returned to baseline or grade 1 or less (except alopecia and labs noted in inclusion criterion #5).\n* Has had major surgery within 3 weeks prior to starting TTI-101 or has not recovered from major side effects due to surgery.\n* Presence of pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures (once monthly or more frequent). Participants with indwelling catheters for control of effusions or ascites are allowed.\n* History of cerebrovascular accident or stroke within the previous 2 years.\n* History of hepatic encephalopathy.\n* Evidence of bleeding diathesis or significant coagulopathy (in the absence of therapeutic anticoagulation).\n* History of malabsorption or other chronic gastrointestinal disease or condition that may hamper compliance or absorption of TTI-101.\n* Pregnant and\u002For breastfeeding. Women of childbearing potential must have a negative serum or urine pregnancy test within 5 days of study entry.\n* HIV-infected if not on effective anti-retroviral therapy with undetectable viral load for 6 months. Patients with HIV who are receiving effective anti-retroviral therapy and have had an undetectable viral load for at least 6 months are eligible. HIV testing not required in the absence of known history of infection.\n* Evidence of chronic hepatitis B virus (HBV) that is detectable on suppressive therapy. Patients with evidence of chronic HBV infection with undetectable HBV viral load on suppressive therapy are eligible. HBV testing not required in the absence of known history of infection.\n* History of hepatitis C virus (HCV) infection that has not been cured or that has a detectable viral load. Patients with a history of HCV that has been treated and cured are eligible. Patients with HCV infection who are currently on treatment and have an undetectable HCV viral load are eligible. HCV testing not required in the absence of known history of infection.",{"count":94,"type":22},24,[96],"PHASE1","The survival rate for patients with pancreatic cancer remains at a dismal 10% or less at 5 years, and although trials integrating stereotactic body radiation therapy (SBRT) alone have shown improvement in local control, initial invigoration of immune response, and relief of symptom burden, SBRT has not demonstrated any improvement in survival. Preclinical research has established that STAT3 inhibition given concurrently with SBRT and in the maintenance phase acts as a synergistic agent that enhances the pro-inflammatory effects of SBRT while reducing its undesired effects (including fibrosis and immunosuppression). This study exploits the window of opportunity post-chemotherapy to advance the hypothesis that the addition of STAT3 inhibition in combination with SBRT will be safe and will enhance 2-year progression-free survival.",[28],[100,101],"borderline resectable","locally advanced",{"date":50,"type":51},{"date":104,"type":51},"2024-01-16",{"date":106,"type":22},"2029-06-30",{"name":108,"class":109},"Washington University School of Medicine","OTHER",2,{"id":112,"slug":113,"hasResults":12,"nctId":114,"briefTitle":115,"officialTitle":116,"acronym":4,"eligibilityCriteria":117,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":118,"enrollmentInfo":119,"targetDuration":4,"studyType":23,"phases":121,"briefSummary":122,"conditions":123,"keywords":4,"overallStatus":47,"whyStopped":4,"lastUpdateSubmitDate":126,"lastUpdatePostDateStruct":127,"startDateStruct":128,"completionDateStruct":130,"leadSponsor":132,"locationsCount":134},"100320607","phase-1-ulixertinibpalbociclib-in-patients-with-advanced-pancreatic-and-other-solid-tumors-100320607","NCT03454035","Ulixertinib\u002FPalbociclib in Patients With Advanced Pancreatic and Other Solid Tumors","Ulixertinib (BVD-523) in Combination With Palbociclib in Patients With Advanced Solid Tumors With Expansion Cohort in Previously Treated Metastatic Pancreatic Cancer and Metastatic RAS-mutant and NF1-mutant (no BRAFV600 Mutations) Melanoma","Inclusion Criteria:\n\n1. Written informed consent and HIPAA authorization for release of personal health information. NOTE: HIPAA authorization may be included in the informed consent or obtained separately.\n2. Age ≥ 18 years at the time of consent (no upper age limit)\n3. Eastern Cooperative Oncology Group (ECOG) Performance Status of ≤ 2\n4. Tumor Eligibility:\n\n   1. Dose escalation cohorts: Histologically confirmed advanced solid tumor refractory to standard of care therapy, or for which there is no accepted standard of care\n   2. Expansion cohort (at RP2D): metastatic pancreatic cancer or malign melanoma patients who have received at least one line of therapy in the metastatic setting\n   3. Expansion cohort (at RP2D) for histologically confirmed unresectable stage III or stage IV melanoma with the following additional eligibility requirements:\n\n      * Tumors molecular profiling genetic aberrations: NRASG12\u002FG13\u002FQ61, KRASG12\u002FG13, HRASG12\u002FG13, any amplifications of the NRAS, KRAS, or HRAS genes. For NF1 mutations, subjects with loss-of-function NF1mutations and without any BRAFV600 mutations will be enrolled.\n      * Documented disease refractory to at least one PD1\u002FPD-L1 inhibitor, defined as disease progression following at least two infusions of the same drug.\n      * Subjects with RAS-mutant and NF1-mutant (no concurrent BRAFV600 mutations) melanoma that have not taken prior immune checkpoint inhibitors will be allowed if they are not eligible to receive prior immune checkpoint inhibitors due to requirement for immunosuppression\n5. Measurable or non-measurable (but evaluable) disease according to RECIST v1.1 for dose escalating cohorts; measurable disease as per RECIST v1.1 required for expansion cohort\n6. Life expectancy ≥ 12 weeks\n7. Recovered from all reversible acute toxic effects of last anti-cancer treatment (other than alopecia) to ≤Grade 1 or baseline. Patients with baseline neuropathy that is ≤ grade 2 are eligible for enrollment.\n8. Demonstrate adequate organ function as defined in the table below; all screening labs to be obtained within 28 days prior to day -6 of ulixertinib\n\n   Hemoglobin (Hgb) ≥ 9 g\u002FdL Absolute Neutrophil Count (ANC) ≥ 1,500 \u002Fmm3 Platelets ≥ 100,000\u002Fmm3 Creatinine ≤1.5 x upper limit of normal (ULN) or Calculated creatinine clearance ≥ 60 mL\u002Fmin using the Cockcroft-Gault formula Bilirubin ≤ 1.5 x ULN Aspartate aminotransferase (AST) and Alanine aminotransferase (ALT) ≤ 2.5 x ULN; if tumor involvement of the liver ≤ 5 x ULN\n9. Adequate cardiac function; left ventricular ejection fraction (LVEF) \\>50% as assessed by ultrasound\u002Fechocardiography (ECHO) and corrected QT interval (QTc)\n10. Females of childbearing potential must have a negative serum pregnancy test within 3 days prior to day -6 of ulixertinib. NOTE: Females are considered of childbearing potential unless they are surgically sterile (have undergone a hysterectomy, bilateral tubal ligation, or bilateral oophorectomy) or they are naturally postmenopausal for at least 12 consecutive months\n11. Females of childbearing potential and males must be willing to abstain from heterosexual activity\\* or use effective methods of contraception from the time of informed consent until 120 days after treatment discontinuation. Acceptable contraception methods can be comprised of an intrauterine device (IUD), vasectomy of a female subject's male partner, contraceptive rod implanted into the skin, OR use of two of the following: diaphragm with spermicide (cannot be used in conjunction with cervical cap\u002Fspermicide), cervical cap with spermicide (nulliparous women only), contraceptive sponge (nulliparous women only), male condom or female condom (cannot be used together), hormonal contraceptive.\\] \\*Abstinence is acceptable if this is the usual lifestyle and preferred contraception for the subject.\n12. Subject is willing and able to comply with study procedures based on the judgment of the investigator or protocol designee.\n13. Willing to provide archival tissue (if available) and consent to mandatory pretreatment and on-treatment biopsy as deemed safe by the treating physician (expansion cohort only) for research purposes only.\n\nExclusion Criteria:\n\n1. Pregnant or breastfeeding (NOTE: breast milk cannot be stored for future use while the mother is being treated on the study)\n2. Treatment with any cancer-directed therapy (chemotherapy, hormonal therapy, biologic, radiation or immunotherapy, etc.) or investigational drug within 28 days or 5 half-lives (whichever is shorter) prior to day -6 of ulixertinib\n3. A history or current evidence\u002Frisk of retinal vein occlusion (RVO) or central serous retinopathy (CSR).\n4. Major surgery within 28 days prior to day -6 of ulixertinib\n5. Not willing to avoid grapefruit, grapefruit juices, grapefruit hybrids, oranges, pummelos, and exotic citrus fruits from 7 days prior to day -6 of ulixertinib and during the entire study due to potential CYP3A4 interaction with the study medications.\n6. Intake of any herbal preparations or medications (including, but not limited to, Saint John's Wort and ginkgo biloba) and dietary supplements within 7 days prior to day -6 of ulixertinib due to potential CYP3A4 interaction with the study medications\n7. Unable or unwilling to discontinue use of any drug known to be a strong inhibitor of CYP3A4, CYP1A2 or CYP2D6 or strong inducer of CYP3A4 (prohibited inducers and inhibitors must be discontinued within 2 weeks prior to day -6 of ulixertinib; see section 10.3 Appendix C)\n8. Unable or unwilling to discontinue use of any drug known to be a sensitive CYP3A4 substrate with a narrow therapeutic index as defined in the protocol.\n9. Central nervous system metastases are allowed only for patients RAS-mutated and NF1-mutant melanoma cohorts (1) no leptomeningeal disease is present, (2) Intracranial disease is controlled by prior therapies, as evidenced by brain imaging 2 weeks post treatment indicating no new intracranial disease, (3) stable or decreasing dose of steroids is provided patient on ≤ 20mg of prednisone or it's equivalent daily.\n10. Any important medical illness or abnormal laboratory finding that would increase the risk of participating in the study (based on the investigator's judgment)\n11. Psychiatric illness\u002Fsocial situations that would limit compliance with study requirements\n12. Has a known additional malignancy that is active and\u002For progressive requiring treatment; non-melanoma skin cancers, non-invasive bladder cancer, and carcinoma in situ of the cervix, prior history of prostate cancer provided the patient is not undergoing active systemic treatment other than hormonal therapy and has documented PSA that is undetectable (\\\u003C0.2ng\u002FmL), prostate carcinoma in remission and did not receive systemic treatment, papillary thyroid cancer did not receive adjuvant radioactive iodine, Stage Rai stage 0 Chronic lymphocytic leukemia does not require systemic treatment, lymphoma, hairy-cell leukemia, or myelodysplasia is in complete remission and or other cancer for which the patient has been disease-free for at least two years.\n\n    Has a known additional malignancy that is active and\u002For progressive requiring treatment.\n13. Impaired GI function or GI disease that may significantly impair absorption (e.g., inflammatory bowel disease (IBD), malabsorption syndrome, small bowel resection, uncontrolled vomiting or diarrhea)\n14. Inability to swallow oral medications\n15. Patients with autoimmune diseases that require systemic corticosteroid treatment \\>20 mg methylprednisolone equivalent.","99 Years",{"count":120,"type":22},45,[96],"This phase I study is designed to establish the safety, maximally tolerated dose (MTD) and recommended phase II dose (RP2D) of the ERK inhibitor ulixertinib (BVD-523) when combined with the CDK4\u002F6 inhibitor palbociclib.",[124,28,125],"Tumor, Solid","Melanoma","2026-08-18",{"date":77,"type":51},{"date":129,"type":51},"2018-01-30",{"date":131,"type":22},"2028-02-03",{"name":133,"class":109},"UNC Lineberger Comprehensive Cancer Center",1,{"id":136,"slug":137,"hasResults":12,"nctId":138,"briefTitle":139,"officialTitle":140,"acronym":4,"eligibilityCriteria":141,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":142,"targetDuration":4,"studyType":23,"phases":144,"briefSummary":145,"conditions":146,"keywords":4,"overallStatus":47,"whyStopped":4,"lastUpdateSubmitDate":149,"lastUpdatePostDateStruct":150,"startDateStruct":151,"completionDateStruct":153,"leadSponsor":155,"locationsCount":157},"100567809","phase-1-ptm-101-in-pancreatic-ductal-adenocarcinoma-pdac-100567809","NCT06673017","PTM-101 in Pancreatic Ductal Adenocarcinoma (PDAC)","A Phase Ib Dose Escalation\u002FDose Expansion Study of PTM-101 as an Adjunct to Neoadjuvant Therapy for Treatment Naïve, Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma (PDAC)","Inclusion Criteria:\n\n* Imaging consistent with primary borderline resectable or locally advanced PDAC. PDAC may be confirmed by histology\u002Fcytology either at study-mandated laparoscopy or by prior biopsy\u002Fcytology\n* Indicated for laparoscopy\n* No prior therapy of any kind for PDAC\n* Acceptable laboratory values\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 - 2\n* Ability to provide informed consent\n* No symptomatic pancreatitis\n* No other active medical issues which would confound interpretation of safety monitoring, efficacy results or prevent the subject from study participation\n* Subjects with childbearing potential must agree to use adequate contraception throughout study participation\n\nExclusion Criteria:\n\n* Active non-pancreatic cancer that currently requires treatment or is being treated; diagnosis of another malignancy within the past 2 years. This criterion excludes a history of carcinoma in situ of the cervix, superficial non-melanoma skin cancers, or superficial bladder cancer that has been adequately treated, or stage 1 prostate cancer that does not require treatment or requires only treatment with luteinizing hormone-releasing hormone agonists or antagonists if initiated at least 30 days prior to screening). Other potentially indolent cancers may be considered.\n* Contraindications or allergies to paclitaxel, PLGA (poly(lactic-co-glycolic ) acid), or contraindications to implantation of PTM-101 or chemotherapies in protocol (e.g., FOLFIRINOX, gemcitabine, nab-paclitaxel)\n* Known history of human immunodeficiency virus (HIV) or active viral hepatitis\n* Active ongoing infection or autoimmune disease which may preclude laparoscopy, placement of PTM-101, administration of chemotherapy or surgical resection of pancreatic tumor\n* Inability to comply with activities and therapeutic interventions as outlined in the schedule of events\n* Currently enrolled in another investigational drug or device trial\n* Women who are pregnant or breastfeeding or who plan to become pregnant or breastfeed; men who plan to donate sperm or conceive a child\n* Any other medical or surgical conditions, including prior abdominal surgery, that would preclude safe laparoscopy or implantation in the opinion of the investigator",{"count":143,"type":22},26,[96],"This is a multi-center, non-randomized, single-arm, open-label, phase Ib, dose escalation\u002Fdose expansion study of PTM-101 when combined with neoadjuvant chemotherapy for the treatment of treatment-naïve subjects with borderline resectable and locally advanced pancreatic ductal adenocarcinoma (PDAC).",[32,147,148,28],"Borderline Resectable Pancreatic Adenocarcinoma","Locally Advanced Pancreatic Adenocarcinoma","2026-08-17",{"date":126,"type":51},{"date":152,"type":51},"2025-04-14",{"date":154,"type":22},"2028-06",{"name":156,"class":58},"PanTher Therapeutics",8,{"id":159,"slug":160,"hasResults":12,"nctId":161,"briefTitle":162,"officialTitle":163,"acronym":164,"eligibilityCriteria":165,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":166,"targetDuration":4,"studyType":23,"phases":168,"briefSummary":170,"conditions":171,"keywords":174,"overallStatus":47,"whyStopped":4,"lastUpdateSubmitDate":179,"lastUpdatePostDateStruct":180,"startDateStruct":181,"completionDateStruct":183,"leadSponsor":185,"locationsCount":134},"100634619","artidis-nanomechanical-signature-profiling-of-pancreatic-cancer-specimens-100634619","NCT07542041","Artidis Nanomechanical Signature Profiling of Pancreatic Cancer Specimens","Artidis Nanomechanical Signature Profiling of Pancreatic Cancer Specimens (ANoPs)","ANoPs","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Ability to understand and willingness to sign a written informed consent form\n* Clinical indication for fine needle biopsy (FNB) of a suspicious pancreatic lesion accessible for biopsy\n\nExclusion Criteria:\n\n* Any condition that, in the opinion of the investigator, makes the subject unsuitable for participation in the study",{"count":167,"type":22},200,[169],"NA","The goal of this clinical study is to evaluate whether the NEO-Match® test, based on ARTIDIS nanomechanical profiling technology, can help predict treatment outcomes and improve clinical decision-making in patients with suspected pancreatic cancer undergoing biopsy.\n\nThe main questions this study aims to answer are:\n\n* Can the NEO-Match® test predict how patients respond to neoadjuvant (pre-surgical) treatment for pancreatic cancer?\n* How well does the NEO-Match® test detect malignant pancreatic lesions compared to standard histopathological assessment?\n\nThis is a prospective, single-arm study. Researchers will compare results from the NEO-Match® test with standard clinical outcomes, imaging findings, and pathology results to evaluate its predictive and diagnostic performance.\n\nParticipants will:\n\n* Undergo a standard-of-care pancreatic biopsy or surgical procedure\n* Provide an additional biopsy sample for research analysis using the ARTIDIS ART-1 device\n* Continue to receive standard treatment and care, which is not influenced by the study\n* Have clinical data, imaging results, and treatment outcomes collected\n* Be followed every 3 months for up to 2 years\n\nThe study does not involve experimental treatment or changes to standard medical care. The information collected may help improve future diagnosis, prognosis, and treatment selection for patients with pancreatic cancer.",[28,172,34,173],"Pancreatic Neoplasms","Pancreatic Lesions Located at the Body or the Tail",[175,176,177,178,32,28],"Atomic Force Microscopy","Neoadjuvant Therapy","Nanomechanical Profiling","NEO-Match","2026-08-15",{"date":126,"type":51},{"date":182,"type":51},"2026-04-17",{"date":184,"type":22},"2030-05",{"name":186,"class":58},"ARTIDIS AG",{"id":188,"slug":189,"hasResults":12,"nctId":190,"briefTitle":191,"officialTitle":192,"acronym":4,"eligibilityCriteria":193,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":194,"enrollmentInfo":195,"targetDuration":4,"studyType":23,"phases":197,"briefSummary":199,"conditions":200,"keywords":205,"overallStatus":47,"whyStopped":4,"lastUpdateSubmitDate":179,"lastUpdatePostDateStruct":210,"startDateStruct":211,"completionDateStruct":213,"leadSponsor":215,"locationsCount":134},"100300428","phase-1-administering-peripheral-blood-lymphocytes-transduced-with-a-murine-t-cell-receptor-recognizing-the-g12v-variant-of-mutated-ras-in-hla-a1101-patients-100300428","NCT03190941","Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients","A Phase I\u002FII Study Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients","* INCLUSION CRITERIA:\n* Measurable (per RECIST V1.1 criteria, metastatic, or unresectable malignancy expressing G12V mutated KRAS as assessed by one of the following methods: RT-PCR on tumor tissue, tumor DNA sequencing, or any other CLIA-certified laboratory test on resected tissue. Patients shown to have tumors expressing G12V mutated NRAS and HRAS will also be eligible as these oncogenes share complete amino acid homology with G12V mutated KRAS for their first 80 N-terminal amino acids, completely encompassing the target epitope.\n* Patients must be HLA-A\\*11:01 positive as confirmed by the NIH Department of Transfusion Medicine.\n* Confirmation of the diagnosis of cancer by the NCI Laboratory of Pathology.\n* Patients must have:\n\n  * previously received standard systemic therapy for their advanced cancer and have been either non-responders or have recurred, specifically:\n\n    * Patients with metastatic colorectal cancer must have had at least two systemic chemotherapy regimens that include 5FU, leucovorin, bevacizumab, oxaliplatin, and irinotecan (or similar agents), or have contraindications to receiving those medications.\n    * Patients with pancreatic cancer must have received gemcitabine, 5FU, and oxaliplatin (or similar agents), or have contraindications to receiving those medications.\n    * Patients with non-small cell lung cancer (NSCLC) must have had appropriate targeted therapy as indicated by abnormalities in ALK, EGFR, or expression of PDL- 1. Other patients must have had platinum-based chemotherapy.\n    * Patients with ovarian cancer or prostate cancer must have had approved first-line chemotherapy.\n\nOR\n\n* declined standard treatment\n* Patients with 3 or fewer brain metastases that are less than 1 cm in diameter and asymptomatic are eligible. Lesions that have been treated with stereotactic radiosurgery must be clinically stable for one month after treatment for the patient to be eligible. Patients\n\nwith surgically resected brain metastases are eligible.\n\n* Age greater than or equal to 18 years and less than or equal to 72 years.\n* Clinical performance status of ECOG 0 or 1\n* Patients must be willing to practice birth control from the time of enrollment on this study and 12 months after the last dose of combined chemotherapy for women and for 4 months after treatment for men.\n* Women of child-bearing potential must be willing to undergo pregnancy testing prior to the start of treatment because of the potentially dangerous effects of the treatment on the fetus.\n\nNOTE: Certain malignancies may secrete hormones that produce false positive pregnancy tests. Serial blood testing (e.g. HCG measurements) and\u002F or ultrasound may be performed for clarification.\n\n* Serology\n\n  * Seronegative for HIV antibody. (The experimental treatment being evaluated in this protocol depends on an intact immune system. Patients who are HIV seropositive may have decreased immune-competence and thus may be less responsive to the experimental treatment and more susceptible to its toxicities.)\n  * Seronegative for hepatitis B antigen, and seronegative for hepatitis C antibody. If hepatitis C antibody test is positive, then patient must be tested for the presence of antigen by RT-PCR and be HCV RNA negative.\n* Hematology\n\n  * ANC greater than 1000\u002Fmm\\^3 without the support of filgrastim\n  * WBC greater than or equal to 2500\u002Fmm\\^3\n  * Platelet count greater than or equal to 80,000\u002Fmm\\^3\n  * Hemoglobin \\> 8.0 g\u002FdL. Subjects may be transfused to reach this cut-off.\n* Chemistry\n\n  * Serum ALT\u002FAST less than or equal to 5.0 times ULN\n  * Total bilirubin less than or equal to 2.0 mg\u002FdL, except in patients with Gilbert s Syndrome, who must have a total bilirubin less than 3.0 mg\u002FdL.\n* Patients must have either an eGFR \\> 60 mL\u002Fm (based on serum creatinine and lab nomogram) or a formal 6-24h CrCl \\> 60 mL\u002Fm.\n* Patients must have completed any prior systemic therapy at the time of enrollment.\n\nNote: Patients may have undergone minor surgical procedures or limited field radiotherapy within the four weeks prior to enrollment, as long as related major organ toxicities have recovered to less than or equal to grade 1.\n\n* Ability of subject to understand and the willingness to sign a written informed consent document.\n* Willing to sign a durable power of attorney.\n* Subjects must be co-enrolled on protocol 03C0277.\n\nEXCLUSION CRITERIA:\n\n* Large volume pulmonary irradiation.\n* Women of child-bearing potential who are pregnant or breastfeeding because of the potentially dangerous effects of the treatment on the fetus or infant.\n* Concurrent systemic steroid therapy.\n* Active systemic infections requiring anti-infective treatment, coagulation disorders, or any other active or uncompensated major medical illnesses.\n* Any form of primary immunodeficiency (such as Severe Combined Immunodeficiency Disease).\n* Concurrent opportunistic infections (The experimental treatment being evaluated in this protocol depends on an intact immune system. Patients who have decreased immune-competence may be less responsive to the experimental treatment and more susceptible to its toxicities.)\n* History of severe immediate hypersensitivity reaction to cyclophosphamide, fludarabine, or aldesleukin.\n* History of coronary revascularization or ischemic symptoms\n* For select patients with a clinical history prompting cardiac evaluation: last known LVEF less than or equal to 45%.\n* For select patients with a clinical history prompting pulmonary evaluation: known FEV1 less than or equal to 50% or DLCO less than 60%.\n* Patients who are receiving any other investigational agents.","72 Years",{"count":196,"type":22},110,[96,198],"PHASE2","Background:\n\nA new cancer therapy involves taking white blood cells from a person, growing them in the lab, genetically modifying them, then giving them back to the person. This therapy is called gene transfer using anti-KRAS G12V mTCR cells.\n\nObjective:\n\nTo see if anti-KRAS G12 V mTCR cells are safe and can shrink tumors.\n\nEligibility:\n\nAdults at least 18 years old with cancer that has the KRAS G12V molecule on the surface of tumors.\n\nDesign:\n\nIn another protocol, participants will:\n\nBe screened\n\nHave cells harvested and grown\n\nHave leukapheresis\n\nIn this protocol, participants will have the procedures below.\n\nParticipants will be admitted to the hospital.\n\nOver 5 days, participants will get 2 chemotherapy medicines as an infusion via catheter in the upper chest.\n\nA few days later, participants will get the anti-KRAS G12V mTCR cells via catheter.\n\nFor up to 3 days, participants will get a drug to make the cells active.\n\nA day after getting the cells, participants will get a drug to increase their white blood cell count. This will be a shot or injection under the skin.\n\nParticipants will recover in the hospital for 1-2 weeks. They will have lab and blood tests.\n\nParticipants will take an antibiotic for at least 6 months.\n\nParticipants will have visits every few months for 2 years, and then as determined by their doctor.\n\nVisits will be 1-2 days. They will include lab tests, imaging studies, and physical exam. Some visits may include leukapheresis or blood drawn.\n\nParticipants will have blood collected over several years.\n\n...",[28,201,202,203,204],"Gastric Cancer","Gastrointestinal Cancer","Colon Cancer","Rectal Cancer",[45,206,207,208,209],"HRAS","NRAS","Cell Therapy","Immunotherapy",{"date":126,"type":51},{"date":212,"type":51},"2017-09-21",{"date":214,"type":22},"2028-06-29",{"name":216,"class":217},"National Cancer Institute (NCI)","NIH",{"id":219,"slug":220,"hasResults":12,"nctId":221,"briefTitle":222,"officialTitle":223,"acronym":4,"eligibilityCriteria":224,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":225,"enrollmentInfo":226,"targetDuration":4,"studyType":23,"phases":228,"briefSummary":229,"conditions":230,"keywords":231,"overallStatus":235,"whyStopped":4,"lastUpdateSubmitDate":236,"lastUpdatePostDateStruct":237,"startDateStruct":238,"completionDateStruct":240,"leadSponsor":242,"locationsCount":4},"100652451","phase-2-retlirafusp-alfa-plus-apatinib-and-chemotherapy-as-second-line-treatment-for-pancreatic-cancer-100652451","NCT07773363","Retlirafusp Alfa Plus Apatinib and Chemotherapy as Second-Line Treatment for Pancreatic Cancer","A Prospective, Open-Label, Single-Arm Clinical Study of Retlirafusp Alfa Combined With Apatinib and Chemotherapy as Second-Line Treatment for Locally Advanced or Metastatic Pancreatic Cancer","Inclusion Criteria:\n\n1. Age 18 to 75 years, male or female.\n2. Histologically or cytologically confirmed unresectable locally advanced or metastatic pancreatic cancer.\n3. ECOG Performance Status of 0 or 1.\n4. Disease progression after first-line systemic therapy.\n5. At least one measurable lesion according to RECIST 1.1, as assessed by the investigator.\n6. Availability of 10 archived tumor tissue sections and 10 mL of peripheral blood.\n7. Adequate organ function.\n8. Women of childbearing potential must have a negative serum or urine pregnancy test within 7 days before enrollment, must not be breastfeeding, and must agree to use effective contraception during the study and for 6 months after the end of study treatment. Male participants must also agree to use effective contraception during the study and for 6 months after the end of study treatment.\n9. Voluntary participation in the study, provision of written informed consent, and willingness and ability to comply with study procedures and follow-up.\n\nExclusion Criteria:\n\n1. Known hypersensitivity to the investigational drug or any of its excipients.\n2. Major surgery, open biopsy, or significant traumatic injury within 4 weeks before study treatment.\n3. Participation in another investigational drug clinical study within 4 weeks before enrollment.\n4. History of other malignancy within the past 5 years, except for malignancies that have been definitively treated and are considered cured.\n5. Any of the following medical conditions: Untreated or symptomatic brain metastases or spinal cord compression. Other active malignancy requiring concurrent treatment.\n\n   Active autoimmune disease or immunodeficiency, or a history of such conditions, including autoimmune hepatitis, interstitial pneumonia, uveitis, rheumatoid arthritis, inflammatory bowel disease, hypophysitis, vasculitis, or nephritis. Exceptions include stable conditions not requiring systemic immunosuppressive therapy, such as type 1 diabetes mellitus, hypothyroidism requiring only hormone replacement therapy, or skin diseases not requiring systemic treatment, such as vitiligo, psoriasis, or alopecia. History of substance abuse or psychiatric disorders that may interfere with study participation.\n6. Severe and\u002For uncontrolled medical conditions, including: Uncontrolled hypertension, defined as systolic blood pressure ≥150 mmHg or diastolic blood pressure ≥100 mmHg. Grade ≥1 myocardial ischemia or myocardial infarction; clinically significant arrhythmia, including QTc ≥450 ms in males or ≥470 ms in females; congestive heart failure of NYHA class ≥II; or LVEF \\\u003C50%. Decompensated diabetes mellitus or other conditions contraindicating high-dose corticosteroid therapy. Exacerbation of chronic obstructive pulmonary disease (COPD) or other severe respiratory disease requiring hospitalization. Active or uncontrolled severe infection (≥Grade 2 according to CTCAE). Uncontrolled pleural effusion, pericardial effusion, or ascites requiring repeated drainage. Cirrhosis, decompensated liver disease, active hepatitis, or chronic hepatitis requiring antiviral treatment. Renal dysfunction with urine protein ≥++ on urinalysis and confirmed 24-hour urinary protein \\>1.0 g.\n7. Severe infection within 4 weeks before the first dose, including infectious complications, bacteremia, or severe pneumonia requiring hospitalization or intravenous antibiotics, antifungal agents, or antiviral therapy; or unexplained fever \\>38.5°C during screening or before the first dose.\n8. Active brain metastases or leptomeningeal metastases at enrollment.\n9. Acute pancreatitis meeting diagnostic criteria or subclinical pancreatitis requiring recent intervention.\n10. Any other condition that, in the investigator's judgment, may prevent the participant from complying with study procedures, restrictions, or requirements.","75 Years",{"count":227,"type":22},37,[198],"This is a prospective, open-label, single-arm clinical study designed to evaluate the efficacy and safety of retlirafusp alfa combined with apatinib and chemotherapy as second-line treatment in patients with unresectable locally advanced or metastatic pancreatic cancer who have experienced disease progression after first-line systemic therapy. Approximately 37 participants will be enrolled. The primary endpoint is progression-free survival (PFS). Secondary endpoints include overall survival (OS), objective response rate (ORR), disease control rate (DCR), duration of response (DOR), and safety.",[28],[28,232,233,234],"Retlirafusp Alfa","Apatinib","Second-Line Treatment","NOT_YET_RECRUITING","2026-08-14",{"date":77,"type":51},{"date":239,"type":22},"2026-08-30",{"date":241,"type":22},"2028-12-30",{"name":243,"class":109},"Tang-Du Hospital",{"id":245,"slug":246,"hasResults":12,"nctId":247,"briefTitle":248,"officialTitle":249,"acronym":250,"eligibilityCriteria":251,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":252,"targetDuration":4,"studyType":23,"phases":254,"briefSummary":255,"conditions":256,"keywords":257,"overallStatus":47,"whyStopped":4,"lastUpdateSubmitDate":236,"lastUpdatePostDateStruct":259,"startDateStruct":260,"completionDateStruct":262,"leadSponsor":264,"locationsCount":7},"100630728","phase-3-study-of-daraxonrasib-and-daraxonrasib--gnp-as-first-line-treatment-in-patients-with-metastatic-pancreatic-adenocarcinoma-100630728","NCT07491445","Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma","RASolute 303: A Phase 3 Global, Multicenter, Open-label, Randomized, 3-Arm Study of Daraxonrasib Monotherapy or Daraxonrasib Plus Gemcitabine and Nab-paclitaxel Versus Gemcitabine and Nab-paclitaxel as a First-Line Treatment for Patients With Metastatic Pancreatic Adenocarcinoma","RASolute 303","Inclusion Criteria:\n\n* At least 18 years old and has provided informed consent.\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.\n* Histologically or cytologically confirmed pancreatic adenocarcinoma.\n* Diagnosis of metastatic disease ≤ 6 weeks prior to informed consent.\n* Documented RAS mutation status, either mutant or wild-type.\n* Measurable disease per RECIST v1.1.\n* Adequate organ function (bone marrow, liver, kidney, coagulation).\n* Able to take oral medications.\n\nExclusion Criteria:\n\n* Prior treatment with systemic anticancer therapy in metastatic setting or prior RAS-targeted therapy in any treatment setting.\n* Active or known history of untreated central nervous system metastatic disease.\n* Any conditions that may affect the ability to take or absorb study drug.\n* Major surgery within 28 days prior to randomization.\n* Patient is unable or unwilling to comply with protocol-required study visits or procedures.",{"count":253,"type":22},900,[25],"The purpose of this study is to evaluate the safety and efficacy of an investigational RAS(ON) inhibitor administered as monotherapy or in combination with chemotherapy, compared with standard of care (SOC) chemotherapy alone.",[28,29,30,31,34,33,35,73],[28,30,32,75,45,207,206,258,76,29,33,73,35],"RAS Wild-Type",{"date":126,"type":51},{"date":261,"type":51},"2026-03-09",{"date":263,"type":22},"2029-03",{"name":84,"class":58},{"id":266,"slug":267,"hasResults":12,"nctId":268,"briefTitle":269,"officialTitle":270,"acronym":271,"eligibilityCriteria":272,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":273,"targetDuration":4,"studyType":23,"phases":275,"briefSummary":276,"conditions":277,"keywords":281,"overallStatus":235,"whyStopped":4,"lastUpdateSubmitDate":296,"lastUpdatePostDateStruct":297,"startDateStruct":298,"completionDateStruct":300,"leadSponsor":302,"locationsCount":4},"100652425","wearable-supported-prehabilitation-and-rehabilitation-for-patients-undergoing-surgery-for-pancreatic-cancer-100652425","NCT07772258","Wearable-Supported Prehabilitation and Rehabilitation for Patients Undergoing Surgery for Pancreatic Cancer","Perioperative Optimisation and Wearable Remote Monitoring of Pancreatic Cancer","POWR-PaC","Inclusion Criteria:\n\n* Adult patients aged 18 years or older.\n* Able to provide informed consent.\n* Able to use the study devices independently or with support from a carer.\n* Approved for pancreatic cancer surgery, including patients undergoing surgery for:\n\nPancreatic cancer Distal cholangiocarcinoma Ampullary carcinoma Duodenal carcinoma Premalignant pancreatic lesions, including Intraductal Papillary Mucinous Neoplasms (IPMNs).\n\n* Clinically stable and considered suitable to participate in the prehabilitation and rehabilitation programme.\n* Owns a smartphone or tablet device\n\nExclusion Criteria:\n\n* Unable or unwilling to provide informed consent.\n* Lacks capacity to provide informed consent.\n* Unstable angina pectoris.\n* Recent myocardial infarction.\n* Recent cerebrovascular accident (stroke).\n* New cardiac arrhythmia.\n* Social, physical, mental health, or substance misuse issues that, in the opinion of the investigator, would jeopardise adherence to study procedures or study contact.\n* No infrastructure for remote monitoring (no access to either mobile signal or Wi-Fi).\n* Clinically unstable or likely to require hospital admission within the next 72 hours.\n* Unable to use the study devices and no carer or support person is available to assist.",{"count":274,"type":22},120,[169],"The goal of this clinical trial is to evaluate whether a wearable-enabled prehabilitation and rehabilitation pathway can improve recovery and post-operative outcomes in adults undergoing surgery for pancreatic cancer or related pancreatic\u002Fperiampullary conditions.\n\nThe main questions it aims to answer are:\n\nDoes a wearable-enabled prehabilitation and rehabilitation programme reduce post-operative complications within 30 and 90 days after surgery? Is the use of wearable devices and remote monitoring feasible, acceptable, and useful for patients and healthcare professionals during the perioperative pathway?\n\nResearchers will compare patients receiving the wearable-enabled pathway with a matched historical control group who received standard care to determine whether the intervention is associated with improved surgical and recovery outcomes.\n\nParticipants will:\n\nProvide informed consent and complete baseline assessments and questionnaires. Take part in the Greater Manchester Prehab4Cancer programme before surgery, including personalised exercise, nutritional support, and wellbeing support.\n\nWear a Corsano CardioWatch device to continuously monitor physiological and activity data.\n\nUse home monitoring equipment, including weight scales and blood pressure monitoring devices.\n\nComplete questionnaires and participant logs during prehabilitation and recovery.\n\nReceive regular support from the research team during participation. Undergo pancreatic surgery and receive standard NHS perioperative care. Continue wearable monitoring and rehabilitation after hospital discharge. Be followed for up to 12 months after surgery using routine clinical data to assess recovery, complications, hospital utilisation, and survival.\n\nOptionally participate in a focus group to discuss their experiences of wearable-enabled care.",[28,172,278,279,280],"Periampullary Carcinoma","Pancreatic Surgery","Perioperative Care",[28,279,280,282,283,284,285,286,287,288,289,290,291,292,293,294,295],"Rehabilitation","Prehabilitation","Exercise","Nutrition","Wearables","Remote Monitoring","Digital Health","Mobile Health","Recovery of Function","Patient Monitoring","Telemedicine","Surgical Oncology","PROMS","Electronic Devices","2026-08-13",{"date":77,"type":51},{"date":299,"type":22},"2026-10-01",{"date":301,"type":22},"2028-09-30",{"name":303,"class":304},"Manchester University NHS Foundation Trust","OTHER_GOV",{"id":306,"slug":307,"hasResults":12,"nctId":308,"briefTitle":309,"officialTitle":310,"acronym":4,"eligibilityCriteria":311,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":4,"targetDuration":4,"studyType":312,"phases":4,"briefSummary":313,"conditions":314,"keywords":316,"overallStatus":328,"whyStopped":4,"lastUpdateSubmitDate":296,"lastUpdatePostDateStruct":329,"startDateStruct":4,"completionDateStruct":4,"leadSponsor":330,"locationsCount":331},"100637017","expanded-access-program-for-daraxonrasib-rmc-6236-in-previously-treated-metastatic-pancreatic-adenocarcinoma-100637017","NCT07573215","Expanded Access Program for Daraxonrasib (RMC-6236) in Previously Treated Metastatic Pancreatic Adenocarcinoma","Expanded Access Program to Treat Patients With Previously Treated Metastatic Pancreatic Adenocarcinoma With Daraxonrasib","Inclusion Criteria:\n\n* At least 18 years old and has provided informed consent.\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.\n* Histologically or cytologically confirmed PDAC with metastatic disease.\n* Evidence of active disease progression during or following the most recent line of systemic therapy for PDAC, based on investigator assessment.\n* At least one prior line of systemic therapy in the metastatic setting, which must include either a fluoropyrimidine-based or gemcitabine-based regimen.\n* Received and progressed, been intolerant to prior standard therapy, or no longer expected to benefit from standard therapies.\n* Adequate bone marrow, renal, hepatic, and coagulation functions.\n* Ineligible for, or unable to enroll in, another clinical trial of daraxonrasib, if available.\n* Able to take oral medications\n\nExclusion Criteria:\n\n* History of known central nervous system metastatic disease.\n* Concurrent systemic anticancer therapy.\n* Significant cardiovascular disease.\n* Major GI conditions that may affect the ability to take or absorb daraxonrasib (patients with prior Whipple procedure are eligible).\n* Active uncontrolled systemic infection.\n* Major surgery within 28 days before enrollment.\n* Additional inclusion and exclusion criteria may apply.","EXPANDED_ACCESS","This Expanded Access Program (EAP) is intended to provide daraxonrasib to eligible adult patients with previously treated metastatic pancreatic adenocarcinoma, who have no comparable or satisfactory alternative therapy and are unable to participate in an ongoing daraxonrasib clinical trial.",[30,31,315,28,29,33,35,73],"Metastatic Pancreas Adenocarcinoma",[317,318,319,320,321,322,323,324,325,326,75,45,29,33,73,35,327],"Expanded Access Program (EAP)","EAP","Daraxonrasib","RMC-6236","RMC-0706236","Metastatic pancreatic adenocarcinoma","Pancreatic ductal adenocarcinoma (PDAC)","RAS(ON) inhibitor","Unmet medical need","Pancreatic cancer","Compassionate Use","AVAILABLE",{"date":149,"type":51},{"name":84,"class":58},241,{"id":333,"slug":334,"hasResults":12,"nctId":335,"briefTitle":336,"officialTitle":337,"acronym":4,"eligibilityCriteria":338,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":339,"targetDuration":4,"studyType":23,"phases":341,"briefSummary":342,"conditions":343,"keywords":346,"overallStatus":47,"whyStopped":4,"lastUpdateSubmitDate":352,"lastUpdatePostDateStruct":353,"startDateStruct":354,"completionDateStruct":356,"leadSponsor":358,"locationsCount":360},"100598066","phase-1-a-study-of-mrg007-arr-217-in-patients-with-advanced-solid-tumors-100598066","NCT07066657","A Study of MRG007 (ARR-217) in Patients With Advanced Solid Tumors","An Open-Label, Multi-Center, Dose Escalation, Confirmation, and Expansion Phase I Clinical Study to Evaluate the Safety, Tolerability, Efficacy, and Pharmacokinetics of MRG007 (ARR-217) in Participants With Unresectable Locally Advanced or Metastatic Solid Tumors","1. Willing to sign the informed consent form and follow the requirements specified in the protocol.\n2. Life expectancy ≥ 3 months.\n3. Tumor specimen available for CDH17 testing, or agree to biopsy at baseline.\n4. Patients with histologically and cytologically confirmed advanced or metastatic solid tumor who have failed or intolerant to standard therapy, or without alternative standard therapy.\n5. Patients must have at least one measurable lesion according to the Response Evaluation Criteria in Solid Tumors (RECIST v1.1).\n6. The score of ECOG for performance status is 0 or 1.\n7. Organ functions and coagulation function must meet the basic requirements.\n8. Patients with childbearing potential must use effective contraception during the treatment and for 6 months after the last dose of treatment.\n\nExclusion Criteria:\n\n1. Patients with more than one cancer.\n2. Received CDH17-targeting anti-tumor therapy; received other investigational product, systemic corticosteroids or surgery for major organs within 4 weeks prior to the first dose; received anti-tumor therapy within 3 weeks or within 5 half-lives prior to the first dose, whichever is shorter; received radiotherapy within 2 weeks prior to the first dose; received strong CYP3A4 inducers or inhibitors within 2 weeks prior to the first dose or 5 half-lives, whichever is longer; investigational therapy within 4 weeks or 5 half-lives (whichever is shorter) prior to the first dose.\n3. ≥Grade 2 toxic reaction or abnormal value of laboratory test caused by previous anti-tumor treatment\n4. Symptomatic Central nervous system and\u002For meninges metastasis.\n5. History of severe cardiovascular diseases\n6. Cerebrovascular accident, pulmonary embolism, or deep venous thrombosis within 3 months prior to the first dose, implantable venous infusion port or catheter-related thrombosis, or superficial venous thrombosis\n7. History of previous or combined interstitial pneumonia, current interstitial pneumonia, or suspected interstitial pneumonia that cannot be ruled out through imaging during screening, severe chronic obstructive pulmonary disease with respiratory failure, severe pulmonary dysfunction, symptomatic bronchospasm, etc.\n8. Poorly controlled pleural, peritoneal, and pelvic effusion, or combined pericardial effusion\n9. Infection of active hepatitis B, active hepatitis C, or HIV\n10. Uncontrolled active bacterial, viral, fungal, rickettsial, or parasitic infections requiring intravenous anti-infection therapy within 2 weeks prior to the first study treatment\n11. Known allergic reactions to any component of MRG007, or known Grade≥3 allergic reactions to other prior anti-CDH17 (including investigational) or other monoclonal antibody.\n12. Other situations that are not suitable to participate a clinical trial per investigator's judgement\n13. Additional protocol-defined exclusion criteria apply",{"count":340,"type":22},572,[96],"This is an open-label, multi-center, phase I study to evaluate the safety, tolerability, efficacy, and pharmacokinetics of MRG007 (ARR-217) in patients with unresectable locally advanced or metastatic solid tumors.",[344,345,201,28],"Locally Advanced or Metastatic Solid Tumors","Colorectal Cancer",[347,348,349,350,351],"MRG007","Advanced or Metastatic Solid Tumors","CDH17","ARR-217","ADC","2026-08-12",{"date":296,"type":51},{"date":355,"type":51},"2025-07-25",{"date":357,"type":22},"2030-12",{"name":359,"class":58},"ArriVent BioPharma, Inc.",21,{"id":362,"slug":363,"hasResults":12,"nctId":364,"briefTitle":365,"officialTitle":366,"acronym":367,"eligibilityCriteria":368,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":369,"targetDuration":4,"studyType":23,"phases":371,"briefSummary":372,"conditions":373,"keywords":383,"overallStatus":47,"whyStopped":4,"lastUpdateSubmitDate":352,"lastUpdatePostDateStruct":388,"startDateStruct":389,"completionDateStruct":391,"leadSponsor":393,"locationsCount":134},"100514215","microenvironment-tumor-effects-of-radiotherapy---comprehensive-radiobiology-assessment-trial-100514215","NCT05975593","MicroEnvironment Tumor Effects of Radiotherapy - Comprehensive Radiobiology Assessment TRial","MicroEnvironment Tumor Effects of Radiotherapy - Comprehensive Radiobiology Assessment TRial (METEOR-CRATR)","METEOR-CRATR","Inclusion Criteria:\n\n* Confirmation of intent to receive radiotherapy for one of the following diagnoses:\n\n  * Cervical cancer\n  * Pancreatic cancer\n* ECOG performance status ≤ 2\n* At least 18 years old\n* Able to understand and willing to sign an IRB-approved written informed consent document\n\nExclusion Criteria:\n\n* Any issue (medical, anatomic, other) that might preclude safe acquisition of biospecimens at the discretion of the treating physician",{"count":370,"type":22},60,[169],"This study is a dynamically adjustable prospective longitudinal study designed to capture biospecimen (biopsy, blood, surgical) and multimodal treatment-related data (imaging, dosimetry, clinical) before, during, and after treatment with definitive-intent chemoradiotherapy for patients with locally advanced cervical and pancreatic cancer.",[374,375,376,377,378,379,380,28,381,382],"Locally Advanced Cervical Carcinoma","Locally Advanced Cervical Cancer","Locally Advanced Pancreas Cancer","Locally Advanced Pancreatic Carcinoma","Locally Advanced Pancreatic Cancer","Cervical Cancer","Pancreas Cancer","Cancer of the Cervix","Cancer of the Pancreas",[384,385,386,326,387],"Radiotherapy","Chemotherapy","Cervical cancer","Biospecimen",{"date":149,"type":51},{"date":390,"type":51},"2024-01-11",{"date":392,"type":22},"2032-12-31",{"name":108,"class":109},{"id":395,"slug":396,"hasResults":12,"nctId":397,"briefTitle":398,"officialTitle":399,"acronym":4,"eligibilityCriteria":400,"healthyVolunteers":401,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":402,"targetDuration":4,"studyType":403,"phases":4,"briefSummary":404,"conditions":405,"keywords":409,"overallStatus":47,"whyStopped":4,"lastUpdateSubmitDate":352,"lastUpdatePostDateStruct":411,"startDateStruct":412,"completionDateStruct":414,"leadSponsor":416,"locationsCount":418},"100311460","a-study-of-blood-based-biomarkers-for-pancreas-adenocarcinoma-100311460","NCT03334708","A Study of Blood Based Biomarkers for Pancreas Adenocarcinoma","Development of Biomarkers for the Early Detection, Surveillance and Monitoring of Pancreatic Ductal Adenocarcinoma","Inclusion Criteria:\n\nCohort 1: Advanced Pancreatic Cancer Cohort Inclusion Criteria\n\n* Radiological, histological or cytological confirmed diagnosis of locally advanced or metastatic pancreatic adenocarcinoma by the enrolling institution\n* Patient planning to receive systemic treatment\n* Hemoglobin \\> 8\n* ECOG performance status 0-2\n* A minimum age of 18 years old\n* Willing to provide permission to obtain banked tumor tissue for analysis (previous biopsies or surgical material).\n\nCohort 2: Operable Pancreatic Cancer Cohort Inclusion Criteria\n\n* Radiological, histological or cytological confirmed diagnosis of pancreatic adenocarcinoma by the enrolling institution\n* Patient planned to undergo upfront resection\n* No pre-operative systemic therapy nor chemoradiation therapy planned\n* Hemoglobin \\> 8\n* ECOG performance status 0-2\n* A minimum age of 18 years old\n* Willing to provide permission to obtain banked tumor tissue for analysis (previous biopsies or surgical material).\n\nCohort 3: Acute Benign Pancreatic Pathology Control Inclusion Criteria\n\n* Confirmed diagnosis of acute pancreatitis or other acute pancreatic pathology by the enrolling institution\n* Hemoglobin \\> 8\n* ECOG performance status 0-2\n* A minimum age of 18 years old\n\nCohort 4: Chronic Benign Pancreatic Pathology Control Inclusion Criteria\n\n* Confirmed diagnosis of chronic pancreatitis or other non-cystic chronic pancreatic pathology by the enrolling institution\n* Hemoglobin \\> 8\n* ECOG performance status 0-2\n* A minimum age of 18 years old\n\nCohort 5: IPMN Control Inclusion Criteria\n\n* Confirmed diagnosis of IPMN without high risk features by the enrolling institution\n* A minimum age of 18 years old\n\nCohort 6: Pancreatic Cyst Control Inclusion Criteria\n\n* Confirmed diagnosis of benign pancreatic cyst by the enrolling institution\n* A minimum age of 18 years old\n\nCohort 7: Healthy Control Inclusion Criteria\n\n* A minimum age of 18 years old\n\nExclusion Criteria:\n\nCohort 1: Advanced Pancreatic Cancer Cohort Exclusion Criteria\n\n* Prior chemotherapy or radiation therapy for pancreatic cancer within the last 3 months in the localized setting\n* Active second malignancy, unless low grade malignancy\n* Any medical or psychiatric condition that may interfere with ability to comply with protocol procedures\n\nCohort 2: Operable Pancreatic Cancer Cohort Exclusion Criteria\n\n* Neoadjuvant chemotherapy or radiation therapy is planned\n* Active second malignancy, unless low grade malignancy\n* Any medical or psychiatric condition that may interfere with ability to comply with protocol procedures\n\nCohort 3: Acute Benign Pancreatic Pathology Control Exclusion Criteria\n\n* Active or prior malignancy, except prior non-melanoma skin cancer\n* Proven to be a carrier of a cancer susceptibility gene or family history concerning for genetic predisposition to cancer\n* Any medical or psychiatric condition that may interfere with ability to comply with protocol procedures\n\nCohort 4: Chronic Benign Pancreatic Pathology Control Exclusion Criteria\n\n* Active or prior malignancy, except prior non-melanoma skin cancer\n* Proven to be a carrier of a cancer susceptibility gene or family history concerning for genetic predisposition to cancer\n* Any medical or psychiatric condition that may interfere with ability to comply with protocol procedures\n\nCohort 5: IPMN Control Exclusion Criteria\n\n* IPMN with high risk features or planned resection\n* Active or prior malignancy, except prior non-melanoma skin cancer\n* Proven to be a carrier of a cancer susceptibility gene or family history concerning for genetic predisposition to cancer\n* Any medical or psychiatric condition that may interfere with ability to comply with protocol procedures\n\nCohort 6: Pancreatic Cyst Control Exclusion Criteria\n\n* Active or prior malignancy, except prior non-melanoma skin cancer\n* Proven to be a carrier of a cancer susceptibility gene or family history concerning for genetic predisposition to cancer\n* Any medical or psychiatric condition that may interfere with ability to comply with protocol procedures\n\nCohort 7: Healthy Control Exclusion Criteria\n\n* Active or prior malignancy, except prior non-melanoma skin cancer\n* Proven to be a carrier of a cancer susceptibility gene or family history concerning for genetic predisposition to cancer\n* Any medical or psychiatric condition that may interfere with ability to comply with protocol procedures",true,{"count":274,"type":22},"OBSERVATIONAL","The purpose of this study is to develop a minimally invasive test to diagnose pancreatic cancer at early stages of disease and monitor response to treatment.",[28,406,407,408],"Pancreatic Diseases","Pancreatitis","Pancreatic Cyst",[410],"17-257",{"date":236,"type":51},{"date":413,"type":51},"2017-10-30",{"date":415,"type":22},"2026-10-30",{"name":417,"class":109},"Memorial Sloan Kettering Cancer Center",13,{"id":420,"slug":421,"hasResults":12,"nctId":422,"briefTitle":423,"officialTitle":424,"acronym":4,"eligibilityCriteria":425,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":194,"enrollmentInfo":426,"targetDuration":4,"studyType":23,"phases":428,"briefSummary":429,"conditions":430,"keywords":434,"overallStatus":47,"whyStopped":4,"lastUpdateSubmitDate":352,"lastUpdatePostDateStruct":437,"startDateStruct":438,"completionDateStruct":440,"leadSponsor":442,"locationsCount":134},"100272786","phase-1-administering-peripheral-blood-lymphocytes-transduced-with-a-cd70-binding-chimeric-antigen-receptor-to-people-with-cd70-expressing-cancers-100272786","NCT02830724","Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers","A Phase I\u002FII Study Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to Patients With CD70-Expressing Cancers","* INCLUSION CRITERIA:\n* For Phase I: Evaluable, unresectable cancer expressing CD70 as assessed by immunohistochemistry of resected tissue (greater than or equal to 2+ CD70 positive on greater than or equal to 50% of cancer cells, or greater than or equal to 1+ CD70 positive on greater than or equal to 75% of cancer cells).\n* For Phase II: Measurable (per RECIST v1.1 criteria), unresectable cancer expressing CD70 as assessed by immunohistochemistry of resected tissue (greater than or equal to 2+ CD70 positive on greater than or equal to 50% of cancer cells, or greater than or equal to 1+ CD70 positive on greater than or equal to 75% of cancer cells).\n* Confirmation of the diagnosis of cancer by the NCI Laboratory of Pathology.\n* Patients must have previously received at least one standard therapy for their cancer (if available) and have been either non-responders (progressive disease) or have recurred.\n* Patients with 3 or fewer brain metastases that are less than or equal to 1 cm in diameter and asymptomatic are eligible. Lesions that have been treated with stereotactic radiosurgery must be clinically stable for 1 month after treatment for the patient to be eligible. Patients with surgically resected brain metastases are eligible.\n* Age greater than or equal to 18 years and less than or equal to 72 years.\n* Clinical performance status of ECOG 0 or 1\n* Patients of both sexes must be willing to practice birth control from the time of enrollment on this study and for 12 months after the last dose of combined chemotherapy for women and for four months after treatment for men.\n* Women of child-bearing potential must be willing to undergo a pregnancy test prior to the start of treatment because of the potentially dangerous effects of the treatment on the fetus.\n\nNOTE: Certain malignancies may secrete hormones that produce false positive pregnancy tests. Serial blood testing (e.g. HCG measurements) and\u002F or ultrasound may be performed for clarification.\n\n-Serology\n\n--Seronegative for HIV antibody. (The experimental treatment being evaluated in this protocol depends on an intact immune system. Patients who are HIV seropositive may have decreased immune-competence and thus be less responsive to the experimental\n\ntreatment and more susceptible to its toxicities.)\n\n* Seronegative for hepatitis B antigen, and seronegative for hepatitis C antibody. If hepatitis C antibody test is positive, then patient must be tested for the presence of antigen by RT-PCR and be HCV RNA negative.\n\n  -Hematology\n* ANC greater than 1000\u002Fmm(3) without the support of filgrastim\n* WBC greater than or equal to 2500\u002Fmm(3)\n* Platelet count greater than or equal to 80,000\u002Fmm(3)\n* Hemoglobin \\> 8.0 g\u002FdL. Subjects may be transfused to reach this cut-off.\n\n  -Chemistry\n* Serum ALT\u002FAST less than or equal to 5.0 times ULN\n* Serum creatinine less than or equal to 1.6 mg\u002FdL\n* Total bilirubin less than or equal to 2.0 mg\u002FdL, except in patients with Gilbert s Syndrome who must have a total bilirubin less than 3.0 mg\u002FdL.\n\n  * Patients must have completed any prior systemic therapy at the time of enrollment.\n\nNote: Patients may have undergone minor surgical procedures or limited field radiotherapy within the four weeks prior to enrollment, as long as related major organ toxicities have recovered to grade 1 or less.\n\n* Ability of subject to understand and the willingness to sign a written informed consent document.\n* Willing to sign a durable power of attorney.\n* Subjects must be co-enrolled on the NCI-SB cell harvest protocol 03-C-0277 (Cell Harvest and Preparation for Surgery Branch Adoptive Cell Therapy Protocols).\n\nEXCLUSION CRITERIA:\n\n* Women of child-bearing potential who are pregnant or breastfeeding because of the potentially dangerous effects of the treatment on the fetus or infant.\n* Concurrent systemic steroid therapy.\n* Active systemic infections requiring anti-infective treatment, coagulation disorders, or any other active or uncompensated major medical illnesses.\n* Any form of primary immunodeficiency (such as Severe Combined Immunodeficiency Disease).\n* History of hematopoietic autoimmune disease or any autoimmune disease requiring immunosuppressive measures.\n* Concurrent opportunistic infections (The experimental treatment being evaluated in this protocol depends on an intact immune system. Patients who have decreased immune-competence may be less responsive to the experimental treatment and more susceptible to its toxicities).\n* History of severe immediate hypersensitivity reaction to cyclophosphamide, fludarabine, or aldesleukin.\n* History of coronary revascularization or ischemic symptoms.\n* For select patients with a clinical history prompting cardiac evaluation: last known LVEF less than or equal to 45%.\n* For select patients with a clinical history prompting pulmonary evaluation: known FEV1 less than or equal to 50% predicted.\n* Patients who are receiving any other investigational agents.",{"count":427,"type":22},124,[96,198],"Background:\n\nIn a new cancer therapy, researchers take a person s blood, select a certain white blood cell to grow in the lab, and then change the genes of these cells using a virus. The cells are then given back to the person. This is called gene transfer. For this study, researchers will modify the person s white blood cells with anti-CD70.\n\nObjectives:\n\nTo see if a gene transfer with anti-CD70 cells can safely shrink tumors and to be certain the treatment is safe.\n\nEligibility:\n\nAdults age 18 and older diagnosed with cancer that has the CD70-expressing cancer.\n\nDesign:\n\nParticipants will be screened with medical history, physical exam, scans, and other tests. They may by admitted to the hospital. Leukapheresis will be performed. For this, blood is removed through a needle in the arm. A machine separates the white blood cells. The rest of the blood is returned through a needle in the other arm.\n\nEligible participants will have an intravenous catheter placed in their upper chest. Over several days, they will get chemotherapy drugs and the anti-CD70 cells. They will recover in the hospital.\n\nParticipants will take an antibiotic for 6 months after treatment. They will repeat leukapheresis.\n\nParticipants will visit the clinic every 1-3 months for the first year after treatment, every 6 months for the second year, and then as determined by their physician. Follow-up visits will take 1-2 days. At each visit, participants will have lab tests, imaging studies, and a physical exam.\n\nThroughout the study, blood will be taken and participants will have many tests to determine the size and extent of their tumor and the treatment s impact.",[28,431,432,125,433],"Renal Cell Cancer","Breast Cancer","Ovarian Cancer",[435,431,208,436,209],"Metastatic Solid Cancers","CAR T-Cells",{"date":296,"type":51},{"date":439,"type":51},"2017-04-06",{"date":441,"type":22},"2030-01-01",{"name":216,"class":217},{"id":444,"slug":445,"hasResults":12,"nctId":446,"briefTitle":447,"officialTitle":448,"acronym":4,"eligibilityCriteria":449,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":225,"enrollmentInfo":450,"targetDuration":4,"studyType":23,"phases":452,"briefSummary":453,"conditions":454,"keywords":4,"overallStatus":47,"whyStopped":4,"lastUpdateSubmitDate":457,"lastUpdatePostDateStruct":458,"startDateStruct":459,"completionDateStruct":461,"leadSponsor":463,"locationsCount":134},"100651641","phase-1-ymn-136-vaccine-for-patients-with-advanced-hepatobiliary-and-pancreatic-malignancies-100651641","NCT07763301","YMN-136 Vaccine for Patients With Advanced Hepatobiliary and Pancreatic Malignancies","YMN-136 Vaccine for Patients With Advanced Hepatobiliary and Pancreatic Malignancies: A Prospective, Phase I Clinical Trial","Inclusion Criteria:\n\n1. Voluntarily sign the informed consent form, and be able to understand and agree to comply with the study procedures and visits as specified in the protocol.\n2. Age: 18 to 75 years old, male or female.\n3. Patients with pathologically or histologically confirmed, unresectable advanced hepatobiliary and pancreatic malignancies who must have experienced disease progression after receiving standard anti-tumor therapy, or who are unable to receive or tolerate standard therapy, or who refuse standard therapy:\n\n(1) Patients with advanced hepatocellular carcinoma who have failed standard therapy, defined as disease progression after prior treatment with PD-(L)1 and mTKI systemic therapy (either separately or in combination), or discontinuation of treatment due to intolerance to toxicity; (2) Patients with advanced biliary tract cancer who have failed standard therapy, defined as disease progression after prior treatment with gemcitabine-containing systemic therapy and non-cytotoxic therapy (i.e., targeted therapy or immunotherapy), or discontinuation of treatment due to intolerance to toxicity; (3) Patients with advanced pancreatic cancer who have failed standard therapy, defined as disease progression after prior treatment with at least two systemic therapies (must include fluoropyrimidines and gemcitabine), or discontinuation of treatment due to intolerance to toxicity.\n\n4\\. Positive IMP3 expression. 5. At least one evaluable lesion according to RECIST v1.1. 6. Eastern Cooperative Oncology Group (ECOG) performance status: 0 or 1. 7. Life expectancy ≥ 12 weeks. 8. Organ function levels at screening must meet the following requirements:\n\n1. Absolute neutrophil count (ANC) ≥ 1.5 × 10⁹\u002FL;\n2. Platelet count (PLT) ≥ 75 × 10⁹\u002FL;\n3. Hemoglobin (Hb) ≥ 90 g\u002FL;\n4. Total bilirubin (TBIL) ≤ 1.5 × ULN;\n5. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.5 × ULN, or ≤ 5 × ULN in patients with liver metastases;\n6. Serum creatinine (Cr) ≤ 1.5 × ULN, or creatinine clearance (Cockcroft-Gault formula) ≥ 45 mL\u002Fmin;\n7. International normalized ratio (INR) and prothrombin time (PT) ≤ 1.5 × ULN;\n8. QTc interval calculated by Fridericia's formula ≤ 450 ms for males and ≤ 470 ms for females;\n9. Urinalysis\u002F24-hour urine protein quantification: urine protein qualitative ≤ 1+ (if urine protein qualitative ≥ 2+, 24-hour urine protein \\\u003C 1 g is acceptable for enrollment);\n10. Cardiac function: left ventricular ejection fraction ≥ 50%. 9. Eligible patients (male or female) with childbearing potential must agree to use a medically accepted physical contraceptive method (e.g., intrauterine device, condom, tubal or vas deferens ligation, etc.) during the study period and for 6 months after the last dose. Female patients of childbearing potential must have a negative serum or urine HCG test at screening.\n\nExclusion Criteria:\n\n1. Presence of extensive peritoneal metastasis or intestinal obstruction.\n2. Presence of uncontrolled pleural effusion, pericardial effusion, or ascites requiring repeated drainage.\n3. Known allergy to any component of the investigational drug (e.g., lipid nanoparticles, RNA carrier) or to drugs of the same class.\n4. Prior receipt of vaccine therapy.\n5. Received chemotherapy, targeted therapy, or immunotherapy within 4 weeks prior to the first dose.\n6. In the dose-escalation and dose-expansion phases: received anti-tumor therapy (including chemotherapy, radiotherapy, targeted therapy, immunotherapy, biological therapy, or other investigational drug therapy for target lesions) within 4 weeks or 5 drug half-lives (whichever is shorter, but at least 14 days) prior to the first dose; or received traditional Chinese medicine or Chinese patent medicine with anti-tumor indications within 14 days prior to the first dose.\n7. Use of immunosuppressive drugs within 4 weeks prior to the first dose or expected use during the study period, except for corticosteroid nasal sprays, inhalers, or systemic prednisone ≤ 10 mg\u002Fday (or equivalent doses of similar drugs).\n8. History of organ transplantation, bone marrow transplantation, or hematopoietic stem cell transplantation.\n9. Receipt of a live attenuated vaccine within 28 days prior to the first dose.\n10. In the dose-escalation and dose-expansion phases: presence of symptomatic, untreated, or central nervous system (CNS) metastases requiring ongoing treatment (including corticosteroids and antiepileptics). Patients with previously treated CNS metastases may be enrolled if they have been clinically stable for at least 4 weeks prior to enrollment, have no evidence of new or enlarging metastases, and have discontinued corticosteroid therapy. Patients with asymptomatic CNS metastases not requiring treatment may be enrolled.\n11. In the dose-escalation and dose-expansion phases: toxicity from prior anti-tumor therapy that has not recovered to baseline or to Grade 0-1 per NCI-CTCAE v5.0 (except for alopecia and hyperpigmentation). Irreversible toxicities that are reasonably not expected to be exacerbated by the study drug may be enrolled after confirmation with the investigator.\n12. History of autoimmune diseases, such as systemic lupus erythematosus, psoriasis requiring systemic therapy, rheumatoid arthritis, inflammatory bowel disease, etc. Patients with type I diabetes mellitus, hypothyroidism controlled with replacement therapy only, or skin diseases not requiring systemic therapy (e.g., vitiligo, psoriasis) may be enrolled.\n13. History of immediate hypersensitivity reactions, eczema, or asthma that cannot be controlled with topical corticosteroids.\n14. History of other malignancies, except for curatively treated curable tumors, such as basal or squamous cell skin cancer, superficial bladder cancer, carcinoma in situ of the cervix, or carcinoma in situ of the breast.\n15. Presence of uncontrolled comorbid conditions, including but not limited to: unexplained fever \\> 38.5°C (patients with tumor-related fever to be enrolled at the investigator's discretion); symptomatic congestive heart failure of New York Heart Association (NYHA) class ≥ 2; left ventricular ejection fraction (LVEF) \\\u003C 50%; poorly controlled hypertension (systolic blood pressure \\> 160 mmHg and\u002For diastolic blood pressure \\> 100 mmHg after treatment, and assessed as clinically significant by the investigator); unstable angina or acute myocardial infarction within 3 months prior to the first dose; poorly controlled arrhythmia; chronic obstructive pulmonary disease, asthma, or interstitial lung disease with impaired pulmonary function.\n16. Presence of active infection currently requiring systemic anti-infective therapy; patients with active tuberculosis.\n17. Known positive for human immunodeficiency virus (HIV) or active syphilis infection; HBsAg and\u002For HBcAb positive with HBV-DNA \\> 500 IU\u002FL; HCV-RNA positive.\n18. Any other condition that, in the investigator's judgment, makes the patient unsuitable for participation in this study, including but not limited to any disease or medical history that may confound the study results or interfere with patient compliance.",{"count":451,"type":22},9,[96],"This study aims to determine the safety and maximum tolerated dose (MTD) of YMN-136 vaccine through a dose escalation trial, and to investigate whether YMN-136 vaccine can assist in the treatment of patients with advanced hepatobiliary and pancreatic malignancies.",[455,28,456],"Liver Cancer","Biliary Tract Cancer (BTC)","2026-08-10",{"date":296,"type":51},{"date":460,"type":51},"2026-08-01",{"date":462,"type":22},"2028-05-31",{"name":464,"class":109},"West China Hospital",{"id":466,"slug":467,"hasResults":12,"nctId":468,"briefTitle":469,"officialTitle":470,"acronym":471,"eligibilityCriteria":472,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":473,"targetDuration":4,"studyType":23,"phases":475,"briefSummary":476,"conditions":477,"keywords":4,"overallStatus":47,"whyStopped":4,"lastUpdateSubmitDate":457,"lastUpdatePostDateStruct":478,"startDateStruct":479,"completionDateStruct":481,"leadSponsor":483,"locationsCount":485},"100577715","topanc-trial-survival-after-total-versus-partial-pancreaticoduodenectomy-for-adenocarcinoma-of-the-pancreatic-head-distal-cholangiocarcinoma-and-ampullary-cancer-100577715","NCT06801899","ToPanc Trial: Survival After Total Versus Partial Pancreaticoduodenectomy for Adenocarcinoma of the Pancreatic Head, Distal Cholangiocarcinoma, and Ampullary Cancer","ToPanc Trial: Survival After Total Versus Partial Pancreaticoduodenectomy for Adenocarcinoma of the Pancreatic Head, Distal Cholangiocarcinoma, and Ampullary Cancer: a Multi-centric Randomized Controlled Trial","ToPanc","Inclusion Criteria:\n\n* Adult patients (age ≥ 18 years) scheduled to undergo PD for highly suspected or histologically proven, resectable pancreatic ductal adenocarcinoma (PDAC), distal cholangiocarcinoma (DCC), and\u002For ampullary cancer (pancreaticobiliary type)\n* Suspected pancreas anastomosis at high-risk for development of a postoperative pancreatic fistula (POPF) (grade \"D\" according to Schuh et al. (29): Estimation by CT scan, MRI, and\u002For Endoscopic Ultrasound\n* Written informed consent\n\nExclusion Criteria:\n\n* Duodenal carcinoma, ampullary cancer (intestinal type), neuroendocrine tumors, benign tumors, chronic pancreatitis\n* Medical conditions that do not allow appreciation of the nature, scope, and possible consequences of the trial as judged by the investigator\n* Pregnancy. A beta-Human Chorionic Gonadotropin (bHCG) pregnancy test must to be performed for women of child-bearing potential (defined as premenopausal women who have not undergone surgical sterilization)\n* Inability to follow the study procedures, e.g., due to psychological disorders, dementia, etc.",{"count":474,"type":22},170,[169],"The goal of this clinical trial is to learn if total removal of the pancreas is a preferable alternative to partial removal in patients with cancer of the pancreatic head who are at high risk of pancreatic leakage. The main question it aims to answer is:\n\nDoes total pancreas removal improve survival without reducing quality of life compared to partial removal?\n\nThe only study specific procedures are the collection of 2 blood samples (7.5ml for each time point, preoperatively and during the hospitalisation) and the completion of the questionnaires.",[28],{"date":352,"type":51},{"date":480,"type":51},"2026-06-01",{"date":482,"type":22},"2030-10",{"name":484,"class":109},"Insel Gruppe AG, University Hospital Bern",10,{"id":487,"slug":488,"hasResults":12,"nctId":489,"briefTitle":490,"officialTitle":491,"acronym":4,"eligibilityCriteria":492,"healthyVolunteers":401,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":493,"targetDuration":495,"studyType":403,"phases":4,"briefSummary":496,"conditions":497,"keywords":499,"overallStatus":235,"whyStopped":4,"lastUpdateSubmitDate":504,"lastUpdatePostDateStruct":505,"startDateStruct":506,"completionDateStruct":507,"leadSponsor":509,"locationsCount":4},"100651624","blood-biomarkers-and-gut-microbiota-for-pancreatic-cancer-risk-in-chronic-pancreatitis-100651624","NCT07762950","Blood Biomarkers and Gut Microbiota for Pancreatic Cancer Risk in Chronic Pancreatitis","Immune Repertoire Decoding Enables Dynamic Risk Stratification During Chronic Pancreatitis-to-Pancreatic Cancer Transition","Inclusion Criteria:\n\n* Adults aged 18 years or older.\n* Able to understand the study procedures and provide written informed consent.\n* Healthy controls: participants without a known history of chronic pancreatitis or pancreatic cancer.\n* Chronic pancreatitis cohort: participants diagnosed with chronic pancreatitis according to clinical guidelines, based on clinical, imaging, and\u002For genetic information.\n* Pancreatic ductal adenocarcinoma cohort: participants with newly diagnosed pancreatic ductal adenocarcinoma based on clinical, imaging, and\u002For pathological evaluation.\n* Willing to provide blood samples and relevant clinical information.\n* For participants with chronic pancreatitis, willing to undergo longitudinal follow-up approximately every 6 to 12 months.\n\nExclusion Criteria:\n\n* Unable or unwilling to provide written informed consent.\n* Unable to provide required clinical information or biological samples.\n* Prior diagnosis of another active malignant tumor, except adequately treated non-melanoma skin cancer or carcinoma in situ, if considered not to affect study participation by the investigator.\n* Current severe acute infection or other serious medical condition that, in the investigator's judgment, may interfere with study participation or interpretation of immune-related analyses.\n* Use of systemic immunosuppressive therapy or immunotherapy within a period considered clinically relevant by the investigator.\n* Any condition that, in the investigator's judgment, makes the participant unsuitable for this study.",{"count":494,"type":22},800,"28 Months","The goal of this observational study is to learn more about pancreatic cancer risk in people with chronic pancreatitis. Researchers will study blood markers and gut microorganisms, which are bacteria and other microbes living in the intestine.\n\nResearchers will compare healthy participants, participants with chronic pancreatitis, and participants with newly diagnosed pancreatic cancer. The study will examine whether blood markers and gut microorganisms differ among these groups. It will also study how these features change over time and whether they may help identify people with chronic pancreatitis who are at higher risk of pancreatic cancer.\n\nParticipants will provide blood and stool samples. Researchers will also collect health information, laboratory test results, and abdominal scan results. Participants with chronic pancreatitis will be followed about every 6 to 12 months. Participants with pancreatic cancer will also be followed according to their routine medical care schedule. Researchers will collect information about their treatment, disease changes, test results, scans, and survival status.\n\nSome participants with chronic pancreatitis or pancreatic cancer may be asked to provide additional blood or stool samples. Their permission will be confirmed before each additional sample is collected. Refusing an additional sample will not affect their routine medical care or continued follow-up in the study.\n\nNo treatment will be assigned as part of this study. The findings may help improve future methods for assessing pancreatic cancer risk in people with chronic pancreatitis.",[498,28],"Chronic Pancreatitis",[32,500,501,502,503],"Serum Biomarkers","Gut Microbiota","Microbial Translocation","Risk Stratification","2026-08-09",{"date":296,"type":51},{"date":460,"type":22},{"date":508,"type":22},"2028-12-31",{"name":510,"class":109},"Changhai Hospital",{"id":512,"slug":513,"hasResults":12,"nctId":514,"briefTitle":515,"officialTitle":516,"acronym":517,"eligibilityCriteria":518,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":225,"enrollmentInfo":519,"targetDuration":4,"studyType":23,"phases":521,"briefSummary":522,"conditions":523,"keywords":527,"overallStatus":47,"whyStopped":4,"lastUpdateSubmitDate":504,"lastUpdatePostDateStruct":536,"startDateStruct":537,"completionDateStruct":539,"leadSponsor":540,"locationsCount":134},"100651415","68ga-sorb-petct-imaging-in-patients-with-solid-tumors-100651415","NCT07760012","68Ga-SorB PET\u002FCT Imaging in Patients With Solid Tumors","A Prospective, Single-Center, Open-Label Exploratory Study of 68Ga-SorB PET\u002FCT Imaging for the Diagnosis of Sortilin-Positive Solid Tumors","SORB-PET","Inclusion Criteria:\n\n* \\- Adults aged 18 to 75 years.\n* Histologically confirmed or clinically suspected melanoma, hepatocellular carcinoma, lung cancer, breast cancer, pancreatic cancer, or ovarian cancer.\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.\n* Adequate hematologic, hepatic, renal, and coagulation function:\n* White blood cell count ≥ 4.0 × 10\\^9\u002FL or absolute neutrophil count ≥ 1.5 × 10\\^9\u002FL;\n* Platelet count ≥ 100 × 10\\^9\u002FL;\n* Hemoglobin ≥ 90 g\u002FL;\n* PT or APTT ≤ 1.5 × upper limit of normal (ULN);\n* Total bilirubin ≤ 1.5 × ULN;\n* ALT and AST ≤ 2.5 × ULN (or ≤ 5 × ULN for participants with liver metastases);\n* ALP ≤ 2.5 × ULN (or ≤ 4.5 × ULN for participants with bone or liver metastases);\n* Blood urea nitrogen and serum creatinine ≤ 1.5 × ULN.\n* Normal cardiac function.\n* Estimated life expectancy of at least 12 weeks.\n* Willing and able to comply with study procedures and follow-up.\n* At least one measurable target lesion according to RECIST version 1.1.\n* Participants of childbearing potential agree to use effective contraception during the study and for 3 months after PET\u002FCT imaging.\n* Clinically indicated to undergo 18F-FDG PET\u002FCT for tumor evaluation.\n* Able to understand the study procedures and provide written informed consent.\n\nExclusion Criteria:\n\n* Pregnant or breastfeeding women.\n* Severe dysfunction of major organs (including heart, liver, or kidney) that, in the investigator's judgment, would make participation inappropriate.\n* Inability to tolerate PET\u002FCT imaging or complete study follow-up.\n* Any other condition that, in the investigator's judgment, makes the participant unsuitable for the study.",{"count":520,"type":22},50,[169],"This prospective, single-center, open-label exploratory diagnostic study aims to evaluate the safety, feasibility, and diagnostic performance of the novel Sortilin-targeted PET tracer 68Ga-SorB in patients with solid tumors. Eligible participants with confirmed or suspected melanoma, hepatocellular carcinoma, lung cancer, pancreatic cancer, breast cancer, or ovarian cancer will undergo 68Ga-SorB PET\u002FCT imaging. The imaging findings will be compared with standard-of-care 18F-FDG PET\u002FCT, using pathology results and\u002For clinical follow-up as the reference standard.\n\nThe primary objectives are to evaluate the safety and tolerability of 68Ga-SorB, assess imaging feasibility, and characterize tumor uptake using quantitative PET parameters, including SUVmax and tumor-to-background ratio (TBR). Secondary exploratory objectives include comparing lesion detection between 68Ga-SorB PET\u002FCT and 18F-FDG PET\u002FCT, assessing diagnostic sensitivity and specificity, evaluating imaging characteristics across different tumor types, and exploring the correlation between Sortilin expression and tracer uptake. This study will provide preliminary clinical evidence supporting the development of Sortilin-targeted molecular imaging and future theranostic applications.",[524,525,526,432,28,433],"Melanoma (Skin Cancer)","Hepatocellular Carcinoma","Lung Cancer",[528,529,530,531,532,533,534,535],"Sortilin","68Ga-SorB","PET\u002FCT","Molecular Imaging","Diagnostic Imaging","Positron Emission Tomography","Radiotracer","Oncology",{"date":352,"type":51},{"date":538,"type":22},"2026-07-24",{"date":508,"type":22},{"name":541,"class":109},"Peking University Third Hospital",{"id":543,"slug":544,"hasResults":12,"nctId":545,"briefTitle":546,"officialTitle":547,"acronym":4,"eligibilityCriteria":548,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":549,"targetDuration":4,"studyType":23,"phases":551,"briefSummary":552,"conditions":553,"keywords":555,"overallStatus":235,"whyStopped":4,"lastUpdateSubmitDate":560,"lastUpdatePostDateStruct":561,"startDateStruct":562,"completionDateStruct":564,"leadSponsor":566,"locationsCount":4},"100650976","first-in-human-study-of-snv1521-with-a-ras-inhibitor-for-people-with-advanced-pancreatic-cancer-100650976","NCT07756281","First in Human Study of SNV1521 With a RAS Inhibitor for People With Advanced Pancreatic Cancer","A Phase 1, Open-Label, Dose-Escalation and Expansion Study of SNV1521 in Combination With RAS Inhibition in Participants With Locally Advanced Unresectable or Metastatic Pancreatic Cancer","Inclusion Criteria:\n\n* Adults (18 years and older).\n* Diagnosis of pancreatic cancer that cannot be removed by surgery or has spread to other parts of the body.\n* Cancer confirmed by tissue or cell examination (histology or cytology).\n* At least one measurable tumor on scans.\n* Good enough general health and organ function to receive study treatment, as judged by the study doctor.\n* Able to swallow oral medicines.\n* Willing to follow study visit schedule and contraception requirements.\n\nExclusion Criteria:\n\n* Serious heart, lung, liver, or other medical problems that would make study treatment unsafe.\n* Active, uncontrolled infections.\n* Other active cancers that could interfere with study assessments (except certain early-stage cancers that have been treated).\n* Prior treatments or medicines that are not allowed by the protocol (for example, some strong drug interactions).\n* Known brain or nervous system involvement from the cancer that is not stable or controlled.\n* Pregnant or breastfeeding, or unwilling to use required birth control during and after the study.",{"count":550,"type":22},40,[96],"This study is a Phase 1 clinical trial testing an oral investigational drug called SNV1521 together with a RAS-targeted cancer medicine in people with pancreatic cancer that cannot be removed by surgery or has spread. The main goals are to find doses of the drug combination that are safe and tolerable and to look for early signs that the treatment may help control the cancer. Participants will receive the study medicines in repeating cycles and will have regular blood tests, scans, and other exams to monitor side effects and how their cancer responds.",[28,554],"Pancreatic Acinar Carcinoma",[556,557,558,559],"daraxonrasib","PARP","pancreas","pancreatic cancer","2026-08-05",{"date":457,"type":51},{"date":563,"type":22},"2026-09",{"date":565,"type":22},"2029-06-01",{"name":567,"class":58},"Synnovation Therapeutics, Inc.",{"id":569,"slug":570,"hasResults":12,"nctId":571,"briefTitle":572,"officialTitle":573,"acronym":4,"eligibilityCriteria":574,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":575,"targetDuration":4,"studyType":23,"phases":577,"briefSummary":578,"conditions":579,"keywords":583,"overallStatus":47,"whyStopped":4,"lastUpdateSubmitDate":560,"lastUpdatePostDateStruct":588,"startDateStruct":590,"completionDateStruct":592,"leadSponsor":594,"locationsCount":143},"100602773","phase-1-a-study-of-phn-012-in-patients-with-advanced-solid-tumors-100602773","NCT07127874","A Study of PHN-012 in Patients With Advanced Solid Tumors","First-in-Human, Phase 1 Study of PHN-012, an Antibody Drug Conjugate, in Patients With Advanced Solid Tumors","Inclusion Criteria:\n\n* Has histologically confirmed, advanced\u002Fmetastatic:\n\n  1. Colorectal adenocarcinoma (CRC), or\n  2. Non-small cell lung cancer (NSCLC), or\n  3. Pancreatic ductal adenocarcinoma (PDAC).\n* Has received at least one prior systemic therapy and radiologically or clinically determined progressive disease during or after the most recent line of therapy, and for whom no further standard therapy is available or who is intolerant to standard therapy.\n* Has measurable disease.\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.\n* Has adequate organ function.\n* Has available tumor tissue sample at screening (either an archival specimen or fresh biopsy material).\n\nExclusion Criteria:\n\n* Had prior treatment with any ADC containing topoisomerase-1 inhibiting payload.\n* Has unstable central nervous system metastasis.\n* Has persistent toxicities from previous systemic anti-cancer treatments of Grade \\>1.\n* Has received systemic anti-neoplastic therapy within five half-lives or 21 days, whichever is shorter, prior to first dose of the study drug.\n* Has received wide-field radiotherapy (\\> 30% of marrow-bearing bones) within 28 days, or focal radiation for analgesic purpose or for lytic lesions at risk of fracture within 14 days prior to first dose of the study drug, or no recovery from side effects of such intervention.\n* Had major surgery (not including placement of vascular access device or tumor biopsies) within 28 days prior to first dose of the study drug, or no recovery from side effects of such intervention.\n* Has a history of non-infectious pneumonitis (NIP) \u002F interstitial lung disease (ILD) requiring systemic steroids within 6 months prior to first dose of the study drug, active NIP \u002F ILD or suspected NIP \u002F ILD which cannot be ruled out by imaging for Screening.",{"count":576,"type":22},165,[96],"This first-in-human study will evaluate safety, tolerability, anti-tumor activity, immunogenicity, pharmacokinetics and pharmacodynamics of PHN-012, a novel antibody-drug conjugate (ADC), in patients with advanced solid tumors.",[203,28,580,581,582],"Lung Cancer (NSCLC)","Advanced Cancer","Advanced Solid Tumors",[584,585,586,587],"Antibody Drug Conjugate","Carcinoma","Cancer","Solid Tumor",{"date":589,"type":51},"2026-08-06",{"date":591,"type":51},"2025-09-23",{"date":593,"type":22},"2028-05",{"name":595,"class":58},"Pheon Therapeutics",{"id":597,"slug":598,"hasResults":12,"nctId":599,"briefTitle":600,"officialTitle":601,"acronym":4,"eligibilityCriteria":602,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":603,"targetDuration":4,"studyType":23,"phases":605,"briefSummary":606,"conditions":607,"keywords":4,"overallStatus":47,"whyStopped":4,"lastUpdateSubmitDate":560,"lastUpdatePostDateStruct":613,"startDateStruct":615,"completionDateStruct":617,"leadSponsor":619,"locationsCount":621},"100573826","phase-1-a-study-of-dm002-in-patients-with-advanced-solid-tumors-100573826","NCT06751329","A Study of DM002 in Patients With Advanced Solid Tumors","A Phase I\u002FIIa, Multicenter, Open-label, First-in-Human, Dose Escalation and Expansion Study of DM002 in Patients With Advanced Solid Tumors","Inclusion Criteria:\n\nCommon Inclusion Criteria (Part 1 and Part 2)\n\n1. Subjects must have the ability to understand and willingness to sign a written informed consent document.\n2. Subjects must be ≥18 years of age at the time of signing the informed consent form.\n3. Subjects must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2.\n4. Has a life expectancy of ≥3 months.\n5. Participants must meet the following laboratory values within 7 days prior to first dose of study drug:\n\n   Note: Transfusion (red blood cell or platelet) or granulocyte-colony stimulating factor (G-CSF) administration is not allowed within 2 weeks prior to laboratory assessments at Screening.\n   * Absolute neutrophil count (ANC) ≥1.5 × 10⁹\u002FL;\n   * Platelet count ≥100 × 10⁹\u002FL;\n   * Hemoglobin ≥9 g\u002FdL;\n   * Calculated creatinine clearance (CrCL) \\>60 mL\u002Fmin (Cockroft-Gault Equation);\n   * Total bilirubin ≤ 1.5 x ULN;\n   * Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤3.0 × upper limit of normal (ULN), if liver metastases are present, ≤5 × ULN;\n   * International normalized ratio (INR)\\\u003C2.0, and prothrombin time and either partial thromboplastin time (PTT) or activated PTT (aPTT) ≤1.5 × ULN, except for participants receiving anti-vitamin K derivative anticoagulant therapy who must have prothrombin time\u002FINR within therapeutic range as deemed appropriate by the Investigator.\n6. Has measurable disease based on RECIST version 1.1.\n7. Participants are required to provide tumor tissue specimens obtained within the previous 3 years for the measurement of MUC1 and\u002For HER3 and other biomarkers. For those subjects who are unable to provide tissue samples will be encouraged (but not mandatory) to undergo biopsy if the risk is manageable. If the biopsy is not possible, it should inform the sponsor for enrolment.\n\nExclusion Criteria:\n\n1. Subjects have another active invasive malignancy within 5 years, with the following exceptions and notes:\n\n   1. History of noninvasive malignancy, such as cervical cancer in situ, in situ melanoma, or ductal carcinoma in situ of the breast that is in complete remission 5 years after treatment with curative intent is allowed.\n   2. Malignancies with a negligible risk of metastasis or death (such as adequately treated basal or squamous cell skin cancer and localized prostate cancer).\n2. Current or history of a hematologic malignancy.\n3. Anticancer therapy (chemotherapy, immunotherapy, hormonal therapy, targeted therapy, biologic therapy, or other anti-cancer therapies, except for hormones for hypothyroidism or estrogen replacement therapy, anti-estrogen analogs, agonists required to suppress serum testosterone levels) within 28 days or 5 half-lives, whichever is shorter, prior to the first study dose. Radiotherapy with a wide field of radiation within 28 days, or radiotherapy with a limited field of radiation for palliation within 14 days of the first study dose. Major surgery, other than diagnostic surgery, within 4 weeks of the first study dose.\n4. Primary central nervous system (CNS) malignancies or CNS metastases. Individuals with brain metastases can be enrolled only if treated, nonprogressive brain metastases and off high-dose steroids (\\>20 mg prednisone or equivalent) for at least 4 weeks.\n5. History of known allergies to ADC, or prior discontinuation of an ADC due to treatment-related toxicities. Has received prior treatment with ADCs that include topoisomerase I (Topo I) payload, and treatment history with any investigational drug within 4 weeks before enrolment in the study.\n6. Has an uncontrolled infection requiring IV injection of antibiotics, antivirals, or antifungals.\n7. Has a pre-existing clinically significant lung diseases (e.g., interstitial pneumonia, pneumonitis, pulmonary fibrosis, and severe radiation pneumonitis) or pre-existing ocular disorders.\n8. Clinically uncontrolled intercurrent illness, including but not limited to an ongoing active infection, active coagulopathy, uncontrolled cardiovascular disease, uncontrolled immune disease, uncontrolled diabetes, uncontrolled pleural and peritoneal effusion, psychiatric illness that would limit compliance with the study requirements and other serious medical illnesses requiring systemic therapies.\n9. Mean resting corrected QT interval corrected by Fridericia's formula (QTcF) \\>470 msec obtained from triplicate 12-lead ECGs at baseline; using concomitant medications that would prolong the QT interval.\n10. Left ventricular ejection fraction \\\u003C50% by either an echocardiogram (ECHO) or a multi-gated acquisition scan within 28 days before first dose of the study drug.\n11. Known active hepatitis B (HBV) or hepatitis C (HCV) infection. Chronic carriers of HBV infection (HBsAg-positive, undetectable HBV DNA or HBV DNA ≤2500 copies\u002Fml or 500 IU\u002Fml) receive prophylactic treatment during the study can be enrolled. Participants with a history of HCV infection have completed curative antiviral treatment and HCV viral load below the limit of quantification and HCV antibody positive but HCV ribonucleic acid (RNA) negative due to prior treatment or natural resolution should be eligible.\n12. Known human immunodeficiency virus (HIV) infection which is not well controlled. Participants should be tested for HIV prior to enrollment if required by local regulations or institutional review board (IRB)\u002Fethics committee. All the following criteria are required to define an HIV infection (positive HIV1\u002F2 antibodies test) that is well controlled: HIV viral load \\\u003C400 copies\u002FmL, CD4+ T- cell counts ≥350 cells\u002FμL, no history of acquired immunodeficiency syndrome-defining opportunistic infection within the past 12 months, and stable viral load for at least 4 weeks on same anti-HIV retroviral medications.\n13. Subjects who are from endemic areas (refer to WHO high tuberculosis burden country list, China is endemic area) will be specifically screened for tuberculosis with any available test. Subjects with active tuberculosis are excluded. Subjects who have received bacille Calmette-Guerin vaccination may have a false positive result of purified-protein derivative (PPD) test. These subjects are eligible if they have a negative result of interferon gamma release assay (IGRA).\n14. Has received a live vaccine within 30 days prior to the first dose of study drug.\n15. Has unresolved toxicities from previous anticancer therapy, defined as toxicities (other than alopecia and anemia) not yet resolved to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 5.0, ≤Grade 1 or baseline. Note: Participants may be enrolled with chronic, stable Grade 2 toxicities (defined as no worsening to \\>Grade 2 for at least 3 months prior to enrolment\u002Frandomization and managed with the standard treatment) that the Investigator deems related to previous anticancer therapy, following discussion with the Sponsor's medical monitor, such as the following: Grade 2 chemotherapy-induced neuropathy, hypothyroidism, hyperglycemia.\n16. Females who are pregnant or lactating or who intend to become pregnant during participation in the study are not eligible to participate.\n17. Participants who are of reproductive potential refuse to use effective methods of birth control during participation of the study and within 7 months for female (and 4 months for male) after the last dose administration.\n18. Participants who took drugs or food which can strongly inhibit or induce the cytochrome P450 (CYP) isoenzyme, CYP3A4\u002F5 within 2 weeks prior to the first dose of DM002 or within 5 half-lives, whichever is longer.",{"count":604,"type":22},280,[96,198],"The goal of study：\n\nThe study has two parts: Part 1 Dose Escalation and Part 2 Dose Expansion.\n\nIn Part 1, a few participants will receive the lowest dose of study drug. The study team will make sure it is safe and tolerated before enrolling new participants at a higher dose of study drug. There will be up to six or more dose levels of study drug tested (called cohorts). Which dose you receive will depend on how many participants have taken part in the study before you.\n\nThe purpose of Part 1 of the study is to evaluate the safety of the study drug at different dose levels, to understand what your body does to the study drug, and to find the best dose of study drug in people who have advanced solid tumor cancers.\n\nIn Part 2, participants will receive the best dose level that was determined in Part 1 of the study.\n\nThe purpose of Part 2 of the study is to evaluate the safety of the study drug at the dose level determined in Part 1, to understand what your body does to the study drug, and to see how your cancer responds to the study drug.\n\nParticipants will:\n\nParticipants will have 17 or more visits to the study centre. This study has a screening phase of up to 28 days , and a treatment phase with cycles of 21 days each. Participants will also have an End of Treatment (EOT) visit 21 days after the final study drug treatment, and a Follow-up visit 30 days after the EOT visit . Participants will be contacted by telephone every 3 months after the Follow-up visit to check on the wellbeing and record any new anticancer therapy they may have started.",[608,609,610,611,612,28],"Ovarian Neoplasms","Prostatic Neoplasms","Endometrial Neoplasms","Colorectal Neoplasms","Solid Carcinoma",{"date":614,"type":51},"2026-08-07",{"date":616,"type":51},"2025-02-17",{"date":618,"type":22},"2028-04-18",{"name":620,"class":58},"Xadcera Biopharmaceutical (Suzhou) Co., Ltd.",7,{"id":623,"slug":624,"hasResults":12,"nctId":625,"briefTitle":626,"officialTitle":626,"acronym":627,"eligibilityCriteria":628,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":629,"targetDuration":4,"studyType":23,"phases":631,"briefSummary":632,"conditions":633,"keywords":4,"overallStatus":47,"whyStopped":4,"lastUpdateSubmitDate":644,"lastUpdatePostDateStruct":645,"startDateStruct":646,"completionDateStruct":648,"leadSponsor":650,"locationsCount":652},"100597545","distance-based-exercise-to-preserve-function-and-prevent-disability-100597545","NCT07059884","Distance-Based Exercise to Preserve Function and Prevent Disability","DEFEND","Inclusion Criteria:\n\n* REGISTRATION ELIGIBILITY CRITERIA (STEP 1): Participants must have histologically confirmed diagnosis of one of the following cancers: anus, bladder, breast, cervix, colon\u002Frectum, endometrium, esophagus, gallbladder, head\u002Fneck, kidney, liver, lung, ovary, pancreas, prostate, sarcoma, stomach\n* REGISTRATION ELIGIBILITY CRITERIA (STEP 1): Participants must be initiating outpatient cytotoxic chemotherapy for curative intent of at least 10 weeks duration (with or without concurrent radiation, immunotherapy, or other targeted therapy). Patients must be enrolled and baseline measures collected on or before administration of their second cycle of cytotoxic therapy. Patients receiving outpatient cytotoxic chemotherapy for curative intent in the neoadjuvant or adjuvant setting are eligible. Patients receiving definitive chemoradiation for the tumors listed above, are also eligible. Regimens of immunotherapy or monoclonal antibodies ONLY are not eligible\n* REGISTRATION ELIGIBILITY CRITERIA (STEP 1): Age 18-64 years\n* REGISTRATION ELIGIBILITY CRITERIA (STEP 1): Patients cannot have metastatic cancer\n* REGISTRATION ELIGIBILITY CRITERIA (STEP 1): Patients cannot have documentation in the medical record of severe cardiovascular, respiratory or musculoskeletal disease or joint problems that preclude moderate physical activity. Examples would include unstable angina, recent myocardial infarction, oxygen-dependent pulmonary disease, and osteoarthritis requiring imminent joint replacement. Moderate arthritis that does not preclude physical activity is not a reason for ineligibility\n* REGISTRATION ELIGIBILITY CRITERIA (STEP 1): Patients cannot be pregnant, because this study involves remotely delivered exercise, and cannot be breast-feeding as patients must be receiving cytotoxic chemotherapy, during which breast-feeding is contraindicated\n* REGISTRATION ELIGIBILITY CRITERIA (STEP 1): Patients cannot have documentation in the medical record of current alcohol, substance abuse, or dementia\n* REGISTRATION ELIGIBILITY CRITERIA (STEP 1): Engaged in full time gainful employment of at least 30 hours per week at the time of cancer diagnosis\n* REGISTRATION ELIGIBILITY CRITERIA (STEP 1): Currently no self-report of engagement in competitive sports (e.g. not training for running races, triathlons, etc.) AND no self-report of twice weekly progressive resistance exercise training for at least 3 consecutive months within the past year\n* REGISTRATION ELIGIBILITY CRITERIA (STEP 1): Self-reported ability to walk for 6 minutes (use of assistive devices will be allowed)\n* REGISTRATION ELIGIBILITY CRITERIA (STEP 1): Not participating in another weight loss, physical activity, or dietary intervention clinical trial\n* REGISTRATION ELIGIBILITY CRITERIA (STEP 1): Predicted 6MWT distance of 550 meters or less\n* REGISTRATION ELIGIBILITY CRITERIA (STEP 1): Concurrent enrollment in treatment or supportive care trials (other than those focused on weight loss or exercise) is allowed with the permission of the Alliance Executive Officer and both studies' study chairs\n* REGISTRATION ELIGIBILITY CRITERIA (STEP 1): Eligibility is restricted to individuals who can comprehend and read English given that participation in the study will require the ability to read intervention materials and work with a coach through telehealth sessions\n* REGISTRATION ELIGIBILITY CRITERIA (STEP 1): The trial is unable to accommodate the needs of deaf or blind participants as the study relies on language and visualization of exercise through telehealth sessions\n* CLINICAL STAKEHOLDER ELIGIBILITY CRITERIA: Clinicians and research staff from enrolling sites who meet following criterion will be deemed eligible to participate as a clinical stakeholder:\n\n  \\* Providing clinical care for participating patients on this study\n* CLINICAL STAKEHOLDER ELIGIBILITY CRITERIA: Ability to speak and understand English\n\nExclusion Criteria:\n\n\\-",{"count":630,"type":22},104,[169],"This clinical trial studies whether an exercise program can be successfully delivered to patients receiving treatment for cancer through virtual sessions and allow patients to exercise in their own home. Treatments for cancer can cause side effects such as fatigue and loss of strength. These side effects can make it difficult to work, take care of family, and do other things the patient wants to do. Preliminary research shows that exercise can help prevent some of these side effects, but it can be more difficult to start an exercise program when a patient is receiving cancer treatment. The exercise program in this study is delivered through telehealth (TH) video calls. The TH sessions are delivered by trained staff that supervise resistance exercises. The trained staff also provide guidance to the patient on completing unsupervised aerobic sessions on their own. This may be a successful way to deliver an exercise program and make it easier for cancer patients to exercise in their own home during treatment.",[634,635,636,432,379,203,637,638,639,201,640,455,526,641,433,28,642,204,643],"Localized Malignant Solid Neoplasm","Anal Cancer","Bladder (Urothelial, Transitional Cell) Cancer","Endometrial Cancer","Esophageal Cancer","Gall Bladder Cancer","Kidney Cancer","Head and Neck Cancer","Prostate Cancer","Sarcoma","2026-08-04",{"date":560,"type":51},{"date":647,"type":51},"2026-02-11",{"date":649,"type":22},"2027-08-31",{"name":651,"class":109},"Alliance for Clinical Trials in Oncology",18,{"id":654,"slug":655,"hasResults":12,"nctId":656,"briefTitle":657,"officialTitle":658,"acronym":659,"eligibilityCriteria":660,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":661,"targetDuration":4,"studyType":23,"phases":663,"briefSummary":664,"conditions":665,"keywords":675,"overallStatus":47,"whyStopped":4,"lastUpdateSubmitDate":644,"lastUpdatePostDateStruct":687,"startDateStruct":688,"completionDateStruct":690,"leadSponsor":692,"locationsCount":694},"100551821","phase-1-a-study-of-ly4052031-in-participants-with-advanced-or-metastatic-urothelial-cancer-or-other-solid-tumors-100551821","NCT06465069","A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors","A Phase 1a\u002F1b Study of LY4052031, an Antibody-Drug Conjugate Targeting Nectin-4, in Participants With Advanced or Metastatic Urothelial Carcinoma or Other Solid Tumors","NEXUS-01","Inclusion Criteria:\n\n* Have one of the following solid tumor cancers:\n\n  * Cohort A1: urothelial carcinoma, triple negative breast cancer, non-small cell lung cancer, esophageal cancer, pancreatic cancer, ovarian cancer, cervical cancer (squamous cell carcinoma), head and neck squamous cell carcinoma or prostate cancer\n  * Cohort A2\u002FB1\u002FB2: urothelial carcinoma\n  * Cohort C: triple negative breast cancer, non-small cell lung cancer, ovarian cancer, cervical cancer, HNSCC (head and neck squamous cell carcinoma), esophageal cancer, pancreatic cancer, or prostate cancer\n* Prior Systemic Therapy Criteria:\n\n  * Cohort A1\u002FC: Individual has received all standard therapies for which the participant was deemed to be an appropriate candidate by the treating investigator; OR there is no standard therapy available for the disease. There is no restriction on number of prior therapies\n  * Cohort A2\u002FB1\u002FB2: Individual must have received at least one prior regimen in the advanced or metastatic setting. There is no restriction on number of prior therapies.\n* Prior enfortumab vedotin specific requirements:\n\n  * Cohorts A1\u002FA2\u002FC: prior treatment with enfortumab vedotin is allowed, but not required\n  * Cohort B1: individual must be enfortumab vedotin naive in the advanced\u002Fmetastatic setting\n  * Cohort B2: individual must have received enfortumab vedotin in the metastatic\u002Fadvanced setting.\n* Measurability of disease\n\n  * Cohort A1: measurable or non-measurable disease as defined by Response Evaluation Criteria in Solid Tumors v1.1 (RECIST 1.1)\n  * Measurable disease is required as defined by Response Evaluation Criteria in Solid Tumors v1.1 (RECIST v1.1) for all Cohorts. Cohort A1 may permit non-measurable disease as defined by RECIST v1.1\n* Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1\n* Have adequate archival tumor tissue sample available or undergo a screening biopsy if allowed per country specific regulations\n\nExclusion Criteria:\n\n* Individual with known or suspected uncontrolled CNS metastases\n* Individual with uncontrolled hypercalcemia\n* Individual with uncontrolled diabetes\n* Individual with evidence of corneal keratopathy or keratitis, and history of corneal transplant\n* Any serious unresolved toxicities from prior therapy\n* Significant cardiovascular disease\n* Recent thromboembolic event and\u002For clinically significant bleeding disorder\n* Prolongation of QT interval corrected for heart rate using Fridericia's formula (QTcF) ≥ 470 ms\n* History of pneumonitis\u002Finterstitial lung disease\n* History of Grade ≥3 skin toxicity when receiving enfortumab vedotin\n* Individuals who are pregnant, breastfeeding or plan to breastfeed during study or within 30 days of last dose of study intervention",{"count":662,"type":22},420,[96],"The purpose of this study is to find out whether the study drug, LY4052031, is safe, tolerable and effective in participants with advanced, or metastatic solid tumors including urothelial cancer. The study is conducted in two parts - phase Ia (dose-escalation, dose-optimization) and phase Ib (dose-expansion). The study will last up to approximately 4 years.",[666,667,668,669,670,671,638,28,433,379,672,642,673,674],"Metastatic Solid Tumor","Recurrent Solid Tumor","Advanced Solid Tumor","Urinary Bladder Neoplasm","Triple Negative Breast Cancer","Non-small Cell Lung Cancer","Head and Neck Squamous Cell Carcinoma","Renal Pelvis Cancer","Bladder Cancer",[674,676,677,678,679,680,673,681,682,683,684,685,686],"Bladder Neoplasm","Bladder Urothelial Carcinoma","Urinary Bladder Cancer","Urinary Tract Cancer","Urothelial Neoplasms","Ureter Cancer","Nectin-4","Antibody Drug Conjugate (ADC)","Triple Negative Breast Cancer (TNBC)","Non-small Cell Lung Cancer (NSCLC)","Head and Neck Squamous Cell Carcinoma (HNSCC)",{"date":560,"type":51},{"date":689,"type":51},"2024-07-01",{"date":691,"type":22},"2027-05",{"name":693,"class":58},"Eli Lilly and Company",39,{"id":696,"slug":697,"hasResults":12,"nctId":698,"briefTitle":699,"officialTitle":700,"acronym":4,"eligibilityCriteria":701,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":702,"targetDuration":4,"studyType":23,"phases":704,"briefSummary":705,"conditions":706,"keywords":710,"overallStatus":235,"whyStopped":4,"lastUpdateSubmitDate":712,"lastUpdatePostDateStruct":713,"startDateStruct":714,"completionDateStruct":716,"leadSponsor":718,"locationsCount":4},"100650768","phase-1-a-study-of-lg00313112-in-participants-with-advanced-solid-malignancies-harboring-a-tp53-y220c-mutation-100650768","NCT07752875","A Study of LG00313112 in Participants With Advanced Solid Malignancies Harboring a TP53 Y220C Mutation","A Phase 1\u002F2, Open-Label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of LG00313112 in Participants With Advanced Solid Malignancies Harboring a TP53 Y220C Mutation","Inclusion Criteria:\n\n1. Males and females aged 18 years or older\n2. Diagnosed locally advanced unresectable or metastatic solid tumor with a TP53 Y220C mutation.\n3. Documented disease progression during or after the most recent line of therapy. In addition, must be refractory to or intolerant of standard of care therapy or have no standard therapy.\n4. Measurable disease per RECIST v1.1.\n5. Eastern Cooperative Oncology Group (ECOG) performance status 0-1.\n6. Adequate organ function.\n\nExclusion Criteria:\n\n1. Investigational therapy or anti-cancer therapy within 21 days or 5 half-lives prior to the first dose of study drug.\n2. Radiotherapy within 14 days prior to the first dose of study drug.\n3. Known brain metastases (Exception: Brain metastases are permitted if the participant is neurologically stable), leptomeningeal disease or carcinomatous meningitis.\n4. Uncontrolled pleural effusion, pericardial effusion, or ascites.\n5. History of myocardial infarction or unstable angina within 6 months prior to enrollment, or clinically significant cardiac disease\n6. Serious infections requiring intravenous antibiotics within 14 days of first dose of study drug.\n7. Active uncontrolled Hepatitis B, Hepatitis C, or human immunodeficiency virus infection\n8. Acute or chronic uncontrolled renal disease, pancreatitis, or liver disease\n9. History of prior organ transplant\n10. Currently receiving strong Cytochrome P4503A (CYP3A4) inhibitors or inducers",{"count":703,"type":22},250,[96,198],"This is a first-in-human, Phase 1\u002F2, open-label study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of LG00313112 in participants with advanced solid malignancies harboring a TP53 Y220C mutation",[433,707,708,345,638,432,637,641,28,709],"Small Cell Lung Cancer","Non Small Cell Lung Cancer","Locally Advanced Unresectable or Metastatic Solid Tumor",[711],"Solid Tumor, TP53 Y220C Mutation","2026-08-03",{"date":614,"type":51},{"date":715,"type":22},"2026-12-01",{"date":717,"type":22},"2033-04-30",{"name":719,"class":58},"LG Chem"]